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Abstract 
Leishmania infantum is a protozoan parasite of the Trypanosomatidae family, 
responsible for human and canine leishmaniasis in Mediterranean countries. Control of 
these vector-borne diseases is unsatisfactory and new chemotherapeutics are urgently 
needed. Trypanothione biosynthesis, owing to its unique and essential character, is 
regarded as an attractive target for therapeutic intervention. Trypanothione is a bis-
(glutathionyl)spermidine conjugate, responsible for redox homeostasis in 
trypanosomatids. It is synthesized by the sequential addition of two molecules of 
glutathione to a spermidine molecule. Trypanothione synthetase (TRYS), which 
catalyzes both conjugation steps, has no counterpart in mammals and is essential to 
Trypanosoma brucei. This scenario is somewhat different in L. infantum, which harbors 
one additional enzyme mono(glutathionyl)spermidine synthetase or GSPS capable of 
driving the first step of trypanothione biosynthesis. Since mono(glutathionyl)spermidine 
can replace some metabolic functions of trypanothione in vitro, the actual significance 
of TRYS is still disputed in GSPS-harboring trypanosomatids. This work aimed at 
clarifying this issue by functionally characterizing both TRYS and GSPS in L. infantum 
promastigotes (insect stage) and amastigotes (mammalian stage), employing a classical 
gene replacement strategy. Concerning TRYS, elimination of both alleles in 
promastigotes was only possible upon complementation with an extrachromosomal 
copy of the gene. Maintenance of this episome for 6 months in the absence of drug 
pressure proved that TRYS is crucial and cannot be replaced by GSPS. Work is on going 
to assess TRYS essentiality in amastigotes. In parallel, we have initiated the chemical 
validation of TRYS using a N
5
-substituted paullone (FS-554) that irreversibly inhibits 
the enzyme in vitro. We observed that the leishmanicidal effect of FS-554 towards 
promastigotes and intramacrophagic amastigotes correlated with TRYS expression 
levels, confirming that this enzyme can be targeted by drug-like compounds in the cell 
context. In what regards GSPS, production of homozygous knockouts is still underway 
to be used in future work. 
Key words: Leishmania infantum, Trypanosomatidae, Trypanothione, Trypanothione 
synthetase, Target validation. 
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Resumo 
Leishmania infantum é um parasita protozoário, da família Trypanosomatidae, causador 
da leishmaniose humana e canina em países Mediterrânicos. As terapias usadas para 
esta doença são ineficazes, sendo urgente descobrir novas fórmulas leishmanicidas. 
Devido ao seu carácter único e essencial, a via biossintética de tripanotiona, é 
considerada um bom alvo terapêutico. Tripanotiona é um ditiol, responsável pelo 
equilíbrio redox em triponassomatídeos, sintetizado pela adição sequencial de duas 
moléculas de glutationa a uma de espermidina. A enzima tripanotiona sintetase (TRYS), 
que catalisa estes dois passos de conjugação, não existe em mamíferos e é essencial em 
Trypanosoma brucei. Em L. infantum, no entanto, existe outra enzima, a 
mono(glutationil)espermidina (GSPS) capaz de catalisar o primeiro passo de síntese. 
Dado que a mono(glutationil)espermidina desempenha algumas das funções 
metabólicas da tripanotiona, a relevância da TRYS em tripanossomatídeos que 
expressam GSPS é discutível. Neste trabalho procurámos clarificar esta questão, tendo 
para isso procedido à caracterização funcional da TRYS e da GSPS em L. infantum, por 
substituição homóloga dos respectivos genes. No que respeita ao gene TRYS, 
verificámos que a eliminação dos dois alelos só foi possível após complementação dos 
parasitas com uma cópia episómica do mesmo. Este episoma conservou-se nos 
parasitas, mesmo após 6 meses de cultura na ausência de qualquer pressão para o 
manter, que não fosse a necessidade de expressar TRYS. Este resultado demonstrou que 
a TRYS é essencial para o estadio de insecto de L. infantum, sem que a GSPS compense 
a sua falta. A mesma estratégia servirá para avaliar o carácter crucial da TRYS no 
estadio de mamífero. Paralelamente, iniciámos a validação química da TRYS usando 
um composto da família química das paulonas (FS-554), que inibe a enzima 
irreversivelmente in vitro. Observámos que uma maior expressão da TRYS confere 
mais resistência à FS-554, confirmando que é possível interferir quimicamente com esta 
enzima no contexto biológico. Relativamente à GSPS, estamos a produzir parasitas 
“knockouts”, não podendo concluir sobre a sua relevância funcional. 
Termos chave: Leishmania infantum, Trypanosomatidae, Tripanotiona, Tripanotiona 
sintetase, Alvo terapêutico. 
  
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
XI 
 
Contents 
 
Acknowledgments / Agradecimentos ................................................................................... V 
Abstract .............................................................................................................................. VII 
Resumo ................................................................................................................................ IX 
Contents ............................................................................................................................... XI 
Content of figures ............................................................................................................. XIII 
Abbreviations .................................................................................................................. XVII 
Introduction ................................................................................................................................... 1 
1. Leishmaniasis .................................................................................................................... 3 
1.1. The disease ................................................................................................................. 3 
1.2. Disease control ........................................................................................................... 5 
2. Leishmania ........................................................................................................................ 6 
2.1. Taxonomy .................................................................................................................. 6 
2.2. Biology ....................................................................................................................... 7 
2.3. Life cycle .................................................................................................................... 9 
3. Quest for new chemotherapies against leishmaniasis ..................................................... 10 
3.1. Strategies for the discovery of new drugs ................................................................ 10 
3.2. The trypanothione system as a potential target for drugs ......................................... 11 
3.3. Trypanothione biosynthesis ...................................................................................... 14 
3.4. Mono(glutathionyl)spermidine biosynthesis ............................................................ 15 
3.5. Targeting the trypanothione system ......................................................................... 15 
4. Aims of the work ............................................................................................................. 16 
Results ......................................................................................................................................... 17 
1. Analysis of TRYS and GSPS amino acid sequences ........................................................ 19 
2. Expression of TRYS along the L. infantum life cycle ...................................................... 22 
3. Genetic validation of TRYS ............................................................................................. 22 
3.1. Generation of heterozygous trys::HYG/TRYS L. infantum parasites ................... 23 
3.2. Attempts to generate L. infantum TRYS null mutants ............................................. 24 
3.3. Generation of L. infantum TRYS null mutants requires previous complementation 
with episomic TRYS ....................................................................................................... 25 
3.4 Maintenance of the pTEX-NEO-TRYS episome in the absence of drug pressure 
confirms gene essentiality in promastigotes .................................................................... 27 
3.6. Assessment of TRYS essentiality in the amastigote stage of L. infantum ............... 29 
4. Chemical validation of TRYS .......................................................................................... 29 
4.1. Preliminary assays .................................................................................................... 29 
   
 
 
4.2. TRYS expression levels correlate with resistance of L. infantum to FS-554 ........... 32 
5. GSPS functional characterization .................................................................................... 34 
5.1. Generation of L. infantum heterozygous gsps::BSD/GSPS parasites .................... 35 
5.2. Attempts to generate L. infantum GSPS null mutants ............................................. 36 
Discussion ................................................................................................................................... 39 
1. General considerations .................................................................................................... 41 
2. TRYS is essential during the insect stage of L. infantum ................................................. 41 
3. LiTRYS can be targeted by drug-like compounds in the cell context ............................. 42 
4. What is the functional relevance of GSPS? ..................................................................... 42 
5. Final remarks ................................................................................................................... 43 
Material & Methods .................................................................................................................... 45 
1. Parasite cultures............................................................................................................... 47 
2. Primers ............................................................................................................................ 47 
3. Transformation of Escherichia coli ................................................................................. 48 
4. General cloning procedures ............................................................................................. 48 
5. Generation of TRYS transfection constructs .................................................................... 48 
6. Generation of GSPS transfection constructs ................................................................... 49 
7. Leishmania infantum transfections .................................................................................. 49 
8. Cryopreservation of L. infantum ..................................................................................... 50 
9. Preparation of genomic DNA from L.infantum ............................................................... 50 
10. Southern blot ................................................................................................................. 50 
11. Western blot .................................................................................................................. 50 
12. Growth curves ............................................................................................................... 51 
13. N
5
-substituded paullones ............................................................................................... 51 
14. Isolation of murine peritoneal macrophages ................................................................. 51 
15. Leishmanicidal effect of N
5
-substituded paullones on intracellular amastigotes .......... 51 
16. Detection of nitric oxide production in macrophages ................................................... 52 
17. Cell viability assays ....................................................................................................... 52 
17.1. Promastigote viability ............................................................................................ 52 
17.2. Macrophages viability ............................................................................................ 52 
18. Geneticin-resistance assays ........................................................................................... 53 
19. In vivo mice infections .................................................................................................. 53 
References ........................................................................................................................... 55 
 
 
   
XIII 
 
Content of figures 
 
Figure 1.1. The Leishmania life cycle. ........................................................................................ 10 
Figure 1.2. The trypanothione system. ........................................................................................ 13 
Figure 2.1. Alignment of the predicted amino acid TRYS sequences of different 
trypanosomatids. ......................................................................................................................... 20 
Figure 2.3. Expression of TRYS during the L. infantum life cycle. ........................................... 22 
Figure 2.4. Shcematic representation of TRYS replacement constructs. ..................................... 23 
Figure 2.5. Generation of L. infantum heterozygous trys
+/-
 promastigotes. ................................ 24 
Figure 2.6. Leishmania infantum parasites obtained upon the second round transfection with the 
PHLEO replacement cassette. ..................................................................................................... 25 
Figure 2.7. Analysis of pTEX-NEO-TRYS complemented trys
+/-
 mutants. ................................ 26 
Figure 2.8. Southern blot analysis of trys
-/-
/+TRYS mutants. ...................................................... 27 
Figure 2.9. Southern blot analysis of trys
-/-
/+TRYS mutants cultured in the absence of geneticin.
 ..................................................................................................................................................... 28 
Figure 2.10. Analysis of pTEX-NEO transfected parasites recovered from mice 9 weeks after 
infection....................................................................................................................................... 29 
Figure 2.11. Preliminary screening of N
5
-substituted paullones on intracellular L. infantum 
amastigotes. ................................................................................................................................. 31 
Figure 2.12. Cytotoxic effect of FS-554 on macrophages and intramacrophagic L. infantum 
amastigotes. ................................................................................................................................. 32 
Figure 2.13. Analysis of TRYS overexpressers. ......................................................................... 33 
Figure 2.14. Correlation between TRYS expression levels and susceptibility of L. infantum 
promastigotes to FS-554.............................................................................................................. 33 
Figure 2.15. Effect of FS-554 on survival of intramacrophagic L. infantum amastigotes 
expressing different levels of TRYS. .......................................................................................... 34 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
XV 
 
Content of tables 
 
Table 1.1. Geographical distribution of human leishmaniasis ...................................................... 5 
Table 2.1. List of N
5
-substituted paullones and their IC50 values against purified recombinant L. 
infantum TRYS. .......................................................................................................................... 30 
Table 2.2. EC50 values of FS-554 against promastigotes expressing different levels of TRYS. . 34 
Table 4.1. List of oligonucleotides employed in this work ......................................................... 47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
XVII 
 
Abbreviations 
AdoMet S-adenosylmethionine 
AdoMetDC S-adenosylmethionine decarboxylase 
ADP  Adenosine diphosphate 
AMP  Beta-lactamase 
ARG  Arginase 
AscPX  Ascrobate peroxidase 
ATP  Adenosine triphosphate 
AIDS  Acquired Immune Deficiency Syndrome 
bp  Base pairs 
BSA  Bovine Serum Albumin 
BSD  Blasticidin S deaminase 
Cf  Crithidia fasciculata 
CHAP  Cysteine, histidine-dependent amidohydrolase/peptidases 
CL  Cutaneous Leishmaniasis 
CO2  Carbon dioxide 
cTXNPx Cytosolic tryparedoxin peroxidase 
dAdoMet Decarboxylated AdoMet 
DAPI  4',6-diamidino-2-phenylindole 
DCL  Diffuse Cutaneous Leishmaniasis 
dCTP  Deoxycytidine triphosphate 
DFMO  Eflornithine 
DMEM  Dulbecco's Modified Eagle's Medium 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
dNTP  Deoxyribonucleotide triphosphate 
Ec  Escherichia coli 
EC50  Half maximal effective concentration 
FBSi  Inactivated fetal bovine serum 
g  gram 
GCL  Glutamate cysteine ligase 
gRNA  Guidance RNA 
GPx  Glutathione peroxidase-like enzyme 
GR  Glutathione reductase 
GSH  Glutathione 
GSP  Mono(glutathionyl)spermidine 
GSPS  Glutathionyl spermidine synthetase 
gsps
+/-
  L. infantum gsps::BSD/GSPS mutants 
G418  Geneticin 
h  Hours 
Hepes  4-(2hydroxyethyl)-1-piperazineethanesulfonic acid 
HYG  Hygromycin phosphotransferase  
IBMC  Institute for Molecular and Cell Biology 
IC50  Half maximal inhibitory concentration 
IFAT  Indirect Fluorescence Antibody Test 
IgG  Immunoglobulin G 
kbp  kilo base pairs 
   
 
 
kDa  kilo Dalton 
kDNA  Kinetoplast DNA 
LB  Lysogeny Broth 
Li  Leishmania infantum 
LC50  Median lethal dose 
Lm  Leishmania major 
M  Molar 
MCL  Mucocutaneous Leishmaniasis  
min  Minutes 
ml  mililiter 
mM  milimolar 
mRNA   Messenger RNA 
mTXNPx Mitichondrial tryparedoxin peroxidase 
mV  milivolt 
NCS  Non-coding sequence 
NMRI  National Marine Research Institute 
NO2
-  
Nitrite 
nM  Nanomolar 
ODC  Ornithine decarboxilase 
O/N  Over Night 
ORF  Open Reading Frame  
PAC  Puromycin N-acetyl-tranferase 
PBS  Phosphate Buffered Saline 
PCR  Polymerase Chain Reaction 
PHLEO Phleomycin hydrolase 
RiboR  Ribonucleotide reductase 
RNA  Ribonucleic acid 
rRNA  Ribosomal RNA 
RPMI  Royal Park Memorial Institute 
Sec  Seconds 
SL  Spliced Leader 
SOC  Super Optimal broth with Catabolite repression 
SPDS  Spermidine synthetase 
Tc  Trypanosoma cruzi 
Tb  Trypanosoma brucei 
TR  Trypanothione reductase 
tRNA  Transfer RNA 
TRYS  Trypanothione synthetase 
trys
+/-  
L. infantum trys::HYG/TRYS mutants 
trys
-/-
/+TRYS L. infantum Δtrys::HYG/Δtrys::PHLEO [pTEX-NEO-TRYS] mutants 
T(SH)2  Trypanothione 
TXN  Tryparedoxin 
U  Unit 
UMSBP Universal minicircle sequence binding protein 
v  Volume 
VL  Visceral Leishmaniasis 
w  Weight 
WHO  World Health Organization 
WT  Wildtype 
   
19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
   
 
 
 
 
 
 
 
 
Chapter 1 
 
Introduction 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  Introduction 
3 
1. Leishmaniasis 
1.1. The disease  
Leishmaniasis is a set of vector-borne diseases with different clinical manifestations, 
caused by several species of the protozoan Leishmania genus. Although frequently regarded as 
a disease of dogs in developed countries, it also affects other mammals, including man, causing 
victims primarily in the tropical and sub-tropical areas of the world. Human leishmaniasis is 
responsible for more than 50,000 fatalities per year and about 350 million people in 88 countries 
all around the world are at risk of contracting the disease. At present, over 12 million 
individuals are estimated to be infected, although the precise number remains elusive due to 
inadequate diagnostic and lack of disease reports. Despite these numbers, the fact that majority 
of cases occur mostly in poor areas of the world renders this disease forgotten by the developed 
countries [1].  
 Leishmaniasis can be transmitted from human to human (anthroponotic transmission) 
or from other mammals to humans (zoonotic transmission). The vector responsible for 
transmission is the female sandfly of the Phlebotomus (Old world) or Lutzomyia (New world) 
genera. Approximately 30 different species transmit leishmaniasis and a single bite is enough to 
establish infection. Depending on the Leishmania species that are transmitted to man, the 
disease can have different clinical manifestations, either as cutaneous leishmaniasis (CL), 
mucocutaneous leishmaniasis (MCL) or visceral leishmaniasis (VL) [2].  
Cutaneous leishmaniasis is the most common form of the disease in humans and, 
despite not being lethal, it dramatically reduces the life quality of patients. This manifestation of 
the disease is characterized by skin lesions that can be localized (nodules or ulcers) or non-
localized (diffuse cutaneous leishmaniasis or DCL). In immunocompetent individuals, infection 
can be controlled and skin lesions usually heal spontaneously leaving trifling scars [3]. 
Mucocutaneous leishmaniasis affects mainly mucosal areas, inducing destructive 
inflammation of nasal, oral and throat mucosal membranes. Unlike CL, this manifestation of the 
disease is not self-healing and sometimes, even upon a successful treatment, it leaves permanent 
disfiguring scars, thus exposing infected individuals to social discrimination and shame [4].  
Visceral leishmaniasis is by far the most aggressive form of the disease and may even 
be fatal if not properly treated. It consists on a systemic infection that can virtually affect any 
macrophage-containing organ, even though liver, spleen, bone marrow and lymph nodes are 
preferentially infected. Common symptoms include high fever, weight loss, anemia, abdominal 
pain, diarrhea and swelling of the liver and spleen [5]. Establishment of a VL infection does not 
always translate into clinical manifestations. Individuals with a fragile immune system, such as 
children and immunosuppressed individuals (e.g. AIDS patients) are usually more susceptible to 
display symptoms. The latter have, actually, been pointed out by the World Health Organization 
Introduction 
  
 
4 
(WHO) as a major problem in VL control. Indeed, while many Leishmania-infected individuals 
remain asymptomatic, HIV-infected patients are 100 to 2300 times more susceptible to develop 
active VL. Likewise, VL accelerates HIV replication and progression [6]. Apart from being 
severely affected, HIV-Leishmania infected patients also contribute to VL dissemination to non-
endemic areas. This scenario is of particular concern in countries of the Mediterranean basin, 
such as Portugal [7]. 
 The incidence of the different manifestations of the disease around the World is tightly 
correlated with the geographical distribution of the different Leishmania species (Table 1.1).  
Leishmaniasis affects mainly poor countries and is frequently associated with poverty, 
malnutrition, illiteracy, weakness of the immune system and lack of resources, having a 
pronounced socio-economic impact in already debilitated communities. The intense human 
migration, added to alterations of the geographical distribution of the insect vector, propelled by 
climate changes, may lead to disease dissemination to non-endemic areas. Still, in developed 
countries the cases of human leishmaniasis remain rare so far [1,8]. In the developed areas of 
the world leishmaniasis has higher impact in veterinary health. This is the case of Portugal, as 
well as other European countries of the Mediterranean basin, where there are numerous cases of 
canine leishmaniasis caused by Leishmania infantum. Importantly, by acting as main reservoirs, 
dogs increase the risk of human transmission due to their proximity to the population [9].   
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   Table 1.1. Geographical distribution of human leishmaniasis 
 
Species 
Disease 
manifestation 
Geographical distribution 
    
 
L. infantum VL 
Mediterranean regions, 
Northern Africa, central Asia 
and northwest China 
 
L. donovani VL 
China, Northern and East 
Africa 
Old 
World 
L. major CL 
Northern Africa, Middle 
East, East Africa and India 
 
L. tropica CL 
Mediterranean regions, 
Afghanistan, northern Africa, 
Middle East and India 
 L. aethiopica CL Ethiopia, Kenya and Uganda 
     L. chagasi VL Central and South America 
New 
World 
L. mexicana CL 
Central and South America 
and south regions of USA 
 L. amazonensis CL South America 
 L. braziliensis MCL Central and South America 
VL, visceral leishmaniasis; CL, cutaneous leishmaniasis; MCL, mucocutaneous 
leishmaniasis. Adapted from Romao [10]. 
 
1.2. Disease control 
At present all efforts to control leishmaniasis have failed the level of demand and 
human beings are currently lagging behind in the battle against this disease. To date there are no 
human vaccines to prevent the disease and the available chemotherapeutic drugs are 
unsatisfactory [reviewed in 11,12]. Means to control leishmaniasis in endemic areas include the 
activity of humanitarian agencies, which promote educational and interventional programs. 
Examples of some of the measures applied in affected nations are control of vector population, 
elimination of reservoir animals and campaigns to raise the population awareness with respect 
to disease symptoms [1]. Additionally, the development of new diagnosis techniques has also 
been encouraged as an important tool to control the disease, as the currently used practices 
involve invasive and risky procedures that are problematic to employ in a third world 
environment [13].  
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 In what concerns chemotherapeutic treatment of leishmaniasis, it currently relies on 
highly toxic antimonial compounds that have been used as first-line drugs since 1945. The most 
commonly used are the trivalent antimony complexes Stibophen
®
, Repodral
®
, Fuadina
®
 and the 
pentavalent antimony complexes Pentostan
®
, Glucantime
®
 and Solustibosan
®
. Furthermore, 
non-antimonial compounds are also used in leishmaniasis treatment as second-choice drugs. 
The most used are Lomidina
®
 (pentamidine), amphotericin B (a macrolide antibiotic) and 
miltefosine (a phospholipid derivative) [3,14]. A lipid formulation of amphotericin B has been 
pointed out as one of the best options in VL treatment. Unfortunately, its prohibitive price and 
parenteral route of administration rule out the application of this drug in poor developing 
countries [15,16].   
Despite the collection of leishmanicidal drugs available, none of them is fully 
satisfactory. In fact they all suffer from either poor efficiency, high toxicity, long-term treatment 
or inconvenient mode of administration. Moreover, in many cases the emergence of drug-
resistant parasites also renders some of the currently used drugs inadequate for leishmaniasis 
treatment [17]. Development of a human vaccine arises as an appealing alternative to the 
chemotherapeutic approach.  However, all attempts to create an efficient and safe vaccine have 
proved unsuccessful so far. The first prophylactic measure against leishmaniasis, known as 
“Leishmanization”, was developed around 1940  and had been used for over 60 years in many 
countries. It consisted in inoculation of virulent Leishmania parasites from a cutaneous lesion 
into healthy individuals. Although still practiced in Uzbekistan, this procedure proved to have 
major adverse effects and has long been abandoned in majority of countries. After 
“Leishmanization”, first-generation vaccines were initially designed to produce a marked 
immune response in the host by injecting live attenuated parasites (i.e. parasites that can infect 
but are not pathogenic) or killed parasites. Second- and third-generation vaccines are more 
sophisticated formulations consisting of purified fractions from Leishmania and purified DNA, 
respectively. Some of these vaccines had their important milestones, but none have successfully 
fulfilled the requirements necessary for a tradable human vaccine. Advances made in canine 
leishmaniasis treatment led to favorable expectations regarding the development of a human 
vaccine [reviewed in 18,19]. To date there are already two registered vaccines to prevent canine 
leishmaniasis, namely Leishmune
®
 in Brazil and Canileish
®
 in Europe [20,21].  
 
2. Leishmania 
2.1. Taxonomy  
Leishmania spp. belong to the order Kinetoplastida, a group of the protozoan phylum 
that includes a number of obligatory parasites affecting a variety of living organisms, including 
plants, insects and vertebrates [22]. Some of these parasites, in particular those of the 
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Trypanosomatidae family are responsible for potentially lethal vector-borne diseases with 
importance in human and veterinary health. The Leishmania genus, along with the 
Trypanosoma genus, represent the two major human pathogens of this family. Currently, more 
than twenty Leishmania species have been described and divided into two subgenera: 
Leishmania Leishmania, which contains both New world and Old world species, and 
Leishmania Viannia, including only New world species. As for the Trypanosoma genus, it also 
includes two pathogen species that cause potentially lethal diseases, namely Trypanosoma cruzi, 
the causative agent of American trypanosomiasis (also known as Chagas’ disease), and 
Trypanosoma brucei, responsible for human African trypanosomiasis (commonly known as 
sleeping sickness) and for the Nagana disease in cattle [23,24].  
 
2.2. Biology 
Kinetoplastids present features common to other eukaryotic cells, like plasma 
membrane, nucleus, nucleolus and ubiquitous organelles. However, these organisms display 
peculiar traits that distinguish them from higher eukaryotes, as detailed next. 
Kinetoplastids are unique for harboring a DNA agglomerate within their single 
mitochondrion, known as kinetoplast or kDNA. This disk-like structure consists of a network of 
two types of circular DNA, a few dozen maxicircles (20-40 kbp) and several thousands 
minicircles (0,5-10 kbp). Maxicircles are responsible for encoding ubiquitous subunits of the 
respiratory chain, as well as two rRNAs molecules, whereas minicircles encode guidance RNAs 
(gRNA) that are implicated in the editing of maxicircles’ transcripts, involving insertion or 
deletion of uridine bases [25]. 
The mitochondrion of kinetoplastids is also unusual for existing as a single, elongated 
ultra-structure that extends along the longitudinal axis of the parasite body. Although it 
comprises the same function of mitochondria in higher eukaryotes (i.e. energy production 
through oxidative phosphorylation), interactions between enzymes of the electron-transfer chain 
differ [26]. Moreover, at least in T. brucei, there are two terminal oxidases involved in the 
electron respiratory chain, the classical cytochrome oxidase and an alternative cytochrome-
independent oxidase [27]. Like in other eukaryotes, most of the proteins of the mitochondrion 
are synthesized in the cytosol and are then imported into this organelle. However, the few 
proteins that are synthesized inside the mitochondrion require recruitment of tRNAs, which are 
not encoded by the mitochondrial genome of kinetoplastids [28]. 
Another distinguishing feature of kinetoplastids is the presence of peroxisome-like 
organelles, known as glycosomes. Except for catalase, these organelles comprise most of the 
enzymes present in peroxisomes of higher eukaryotes, namely those involved in β-oxidation of 
fatty acids, biosynthesis of pyrimidines and purine salvage pathways. What renders glycosomes 
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unique is the compartmentalization of part of the glycolytic pathway (glucose to glycerate 3-
phosphate conversion), which in higher eukaryotes occurs in the cytosol. Compartmentalization 
of glycosis in these organelles may allow a more efficient and independent control over glucose 
consumption in situations of unfavorable ATP/ADP ratio inside cells [29].  
In what concerns molecular biology, trypanosomatids possess a highly plastic genome, 
characterized by fluctuations in the number and size of chromosomes, as well as by the  
amplification of large regions of the genome, a phenomenon that is usually associated with drug 
resistance [30,31]. In addition, during mitosis nuclear membrane of trypanosomatids is not 
disrupted and chromatin condensation is not observed during chromosome segregation [32]. 
Also notably, DNA transcription in these organisms presents some exclusive traits with 
miscellaneous characteristics between eukaryotes and prokaryotes. In particular, genes without 
any functional relation are transcribed as large polycistronic units that undergo a trans-splicing 
mechanism before transduction. In this process a small capped RNA (spliced leader or SL) is 
added at the 5’ end of each coding region, followed by a non-specific sequence polyadenylation 
at the 3’-end. Intriguingly, trypanosomatids lack classical eukaryote or prokaryote promoter 
regions and to date no consensus regions have been found that can be regarded as promoters. 
This fact, along with the polycistronic nature of their mRNA, deprives trypanosomatids from 
transcription control of individual genes. Usually, transcription initiates between two gene 
clusters with divergent transcription directions, i.e. towards or away from the telomeres. Even 
though there are no obvious promoter sequences in the genome of trypanosomatids, untranslated 
regions flanking coding sequences are known to be important to regulate gene expression 
[reviewed in 33,34].    
Finally, the thiol metabolism in these organisms presents many differences towards 
other eukaryotes. Briefly, they possess a unique conjugate of glutathione (GSH) and spermidine, 
known as trypanothione that takes over most of the functions of GSH in higher eukaryotes. The 
unique characteristics of this thiol and how these can be explored for drug development will be 
detailed in section 3.2. of the Introduction. 
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2.3. Life cycle 
Leishmania, as well as other members of the Trypanosomatidae family, have a digenetic 
life cycle during which they suffer major morphological and biochemical modifications (Figure 
1.1) that are associated to two distinct life stages: i) the promastigote, an elongated, extracellular 
single flagellated form that resides inside the alimentary tract of the vector, and ii) the 
amastigote, a non-motile aflagellated round shaped form that thrives inside macrophages of the 
host. 
When an insect vector feeds on the blood of an infected host it ingests amastigote-
containing macrophages and initiates the infection cycle. Inside the insect digestive tract, 
amastigotes are released from macrophages and immediately begin to differentiate into 
promastigostes. On the subsequent 6-10 days, significant morphological and biochemical 
changes occur, ultimately culminating in the migration of the promastigote infective form 
(metacyclic promastigotes) into the thoracic midgut and proboscis of the sandfly. By this time, 
if the infected vector feeds on a mammalian host, it will deposit several thousands of metacyclic 
promastigotes into its skin [35]. Parasite inoculation immediately triggers an immune response 
with the concomitant recruitment of phagocytic cells, like neutrophils, dendritic cells and 
macrophages, to the site of inoculation. Leishmania can subsequently be phagocytized by any of 
these cells, through a receptor-mediated phagocytosis mechanism. The role of neutrophils and 
dendritic cells during Leishmania invasion is still disputed. However, it is within mononuclear 
phagocytes that the parasite replicates and persists [36,37]. Inside these cells, parasites reside in 
phagolysosomes (the outcome of the fusion of a phagosome with a lysosome), where they revert 
into amastigotes and multiply by binary fission. Massive multiplication in these acidic vacuoles 
eventually leads to macrophage burst, after which parasites can be phagocytized again by other 
macrophages, in this way perpetuating the amastigote cycle inside the host [38].  
For research purposes, both Leishmania life cycle stages can be cultured in vitro, in 
appropriate medium and conditions. Promastigotes are cultured at 25 ºC in a neutral buffered 
medium (pH=7), reflecting the environment found in the alimentary tract of the insect vector, 
whereas amastigotes can be grown axenically in acidic medium (pH=5) at 37 ºC, mimicking the 
conditions inside phagolysosomes. Alternatively, the amastigote stage can also be studied 
intracellularly in ex vivo infections of macrophage cultures.   
 
 
  
Introduction 
  
 
10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. The Leishmania life cycle. During a blood meal, the female sandfly ingests macrophages 
containing amastigotes that are released in the insect midgut (1). Amastigotes differentiate into 
promastigotes (2) and these go through a series of differentiation phases that culminate in metacyclic 
infective forms (3). The infected sandfly feeds on a mammalian host, injecting metacyclic promastigotes 
into the host skin (4), where they are internalized by phagocytic cells (5). Parasite-containing phagosomes 
fuse with lysosomes, forming phagolysosomes, wherein promastigotes revert into amastigotes (6) and 
begin to replicate by binary fission (7), leading to the burst of phagocytes. Released amastigotes can be 
taken up by other phagocytes, in this way perpetuating the amastigote stage inside the mammalian host 
(8). Adapted from Kaye et al. [39]. 
 
3. Quest for new chemotherapies against leishmaniasis 
3.1. Strategies for the discovery of new drugs 
The unsatisfactory traits of current therapies against leishmaniasis, together with disease 
dissemination and the increasing reports of drug-resistant parasites, renders the development of 
new leishmanicidals a mandatory issue. The urgency to find new drugs arises as a major 
concern to researchers all around the world and efforts to increase the drug pipeline has been 
made in the last few years, mostly at the academic level. Two main strategies have been applied 
to pursuit this goal. One employs high-throughput drug screening trials, sometimes using 
compounds already established in the market, in order to find antiparasitic drugs. Selected 
compounds can then be exploited to understand their specific mode of action and, if necessary 
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and possible, considered to be chemically modified to increase target specificity [40]. The other 
strategy, known as rational drug design, consists in identifying molecular targets that are 
essential to parasite survival, so that their depletion or inactivation leads to parasite death. In 
this context, a deep knowledge of the parasite biochemistry is crucial to find a good candidate 
that can be inhibited by drug-like compounds inside the macrophages of the mammalian host. 
This approach employs several interdisciplinary techniques, from molecular/cell biology to 
biochemistry and computer sciences, to assess the likelihood of a molecule to be used as drug 
target. The appraisement of a certain gene candidate to serve as a drug target includes its 
validation both at the genetic and the chemical level, as detailed next.  
Genetic validation consists in evaluating the essentiality of a given gene during the life 
cycle of the parasite, resorting to common molecular and genetic techniques. Abrogation of 
gene expression is pursued and associated phenotypic changes evaluated. In the case of most 
Leishmania spp., where interference RNA or inducible expression systems are either absent or 
still deficient, this is usually achieved by a classical gene knockout strategy. This consists in 
replacing the gene of interest by other that confers resistance to a toxic drug. Since Leishmania 
are diploid organisms, elimination of both alleles requires two rounds of homologous 
recombination with different drug resistance markers. Following this approach, there are two 
possible outcomes: i) parasites grow normally throughout their complete life cycle, with no 
apparent phenotypic alterations, indicating that the target gene is not essential for parasite 
survival, hence not suitable as drug target; ii) elimination of both gene alleles is not compatible 
with parasite life, indicating that the gene may be further exploited for therapeutic purposes 
[41]. 
Chemical validation is a complement of the genetic validation. It consists of using a 
known inhibitor of the target molecule to verify whether its inactivation affects parasite 
viability. This approach addresses important “druggability” issues, namely the possibility of 
blocking the target molecule with low effective concentrations (EC50) of drug like-compounds 
in the cell context to impair parasite survival.  
In short, following a rational drug design strategy, a gene to be regarded as a valid 
target for drugs has to fulfill the requirements of essentiality, exclusiveness and susceptibility to 
inhibition in the medically relevant life stage of the parasite. 
 
3.2. The trypanothione system as a potential target for drugs 
In the quest to find new drug targets, the thiol system of trypanosomatids has received 
much attention in the last two decades owing to its unique character. Unlike most living 
organisms, trypanosomatids lack the conventional GSH/GSH-reductase (GR) redox couple that 
is responsible for maintaining a reducing intracellular environment. Instead, this function is 
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largely accomplished by the trypanosomatids’ unique thiol, N1,N8-bis(glutathionyl)spermidine, 
also known as trypanothione [T(SH)2]. This molecule is the major low molecular mass thiol in 
trypanosomatids and plays a pivotal role in many essential metabolic pathways [reviewed in 42].  
Trypanothione was first described in 1985 by Alan Fairlamb and co-workers in C. 
fasciculata, a member of the trypanosomatid family that is noninfectious to mammals [43]. It is 
a small dithiol, formed by one spermidine molecule (a cationic polyamine) with two GSH 
molecules covalently bound to its terminal amino groups. Originally considered as a co-
substrate of GR, the actual role of T(SH)2 was only elucidated upon the finding that 
typanosomatids do not possesses GR and that, instead, harbor a trypanothione reductase (TR) 
enzyme. It is now well established that in trypanosomatids the T(SH)2/TR system replaces most 
of the functions played by the GSH/GR redox couple in mammalian cells. Even though GSH is 
also present in trypanosomatids, it is thought to play a minor role in the redox metabolism of 
parasites, as all enzymes that in mammals depend on GSH are either absent in these organisms 
(e.g. GR and selenium-containing GSH peroxidases) or preferentially utilize T(SH)2 as reducing 
substrate [44,45].  
When compared with GSH, T(SH)2 is a more reactive, positively charged molecule 
capable of spontaneously reducing different biological disulfides [46]. This higher reactivity is 
not attributed to its redox potential (-242 mV), which does not significantly differ from that of 
GSH (-230 to -250 mV) [47]. Rather, it is the pKa value of the thiol groups of trypanothione 
(7.4) that contributes to its increased reactivity relative to that of GSH (pKa of 8.7-9.2) [48]. 
This is explained by the fact that thiol-disulfide exchange reactions are highly favored when the 
pKa value of the thiol is proximal to the pH value of the surrounding medium. Moreover, the 
dithiol nature of T(SH)2 allows the formation of an intramolecular disulfide bond that is 
kinetically favored relative to intermolecular disulfide bonds, as occurs in oxidized GSH 
(GSSG) [49]. 
 Trypanothione is directly or indirectly involved in many metabolic processes (Figure 
1.2), from redox state regulation (by maintaining thiol redox homeostasis) to elimination of 
toxic compounds (including detoxification of reactive oxygen species and extrusion of toxic 
compounds via a trypanothione-S-transferase) [50-52] and DNA replication [by providing 
reducing equivalents to ribonucleotide reductase and to the universal minicircle sequence 
binding protein (UMSBP)] [53,54]. Many of these T(SH)2-dependent pathways have been 
genetically validated as drug targets in the past [42]. Accordingly, inhibition of trypanothione 
biosynthesis should disturb many of these vital metabolic routes, eventually leading to parasite 
death. This, added to the unique character of this thiol, renders the T(SH)2 biosynthesis pathway 
an attractive option when considering potential drug targets for trypanosomatids. 
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Figure 1.2. The trypanothione system. 
1. De novo synthesis of trypanothione [T(SH2)] is achieved by the ATP-dependent conjugation of two 
GSH molecules to spermidine. This reaction is catalyzed by trypanothione synthetase (TRYS), which in 
T. brucei was proven to be essential for parasite survival [55,56]. 
2. The first GSH conjugation can also be catalyzed by the GSPS enzyme to produce N
1 
or N
8
-
mono(glutathionyl)spermidine (GSP). This compound have been suggested to replace some of the T(SH)2 
functions [57-59].  
3. Trypanothione is the major thiol of trypanosomatids and is essential to many vital pathways. It delivers 
reducing equivalents to the enzymes of this system.  
4. Trypanothione reductase (TR) is a flavin-containing disulfide reductase responsible for maintaining 
T(SH)2 in the reduced state. This enzyme was shown to be essential for the survival of several 
trypanosomatids and is one of the most exploited drug targets in these organisms [60]. 
5. Trypanothione reduces cytosolic tryparedoxins (cTXN) [61], which provide the reducing equivalents to 
the peroxiredoxin-type tryparedoxin peroxidases (cTXNPx) [62,63] and to non-selenium glutathione 
peroxidase-like enzyme (cGPx) [64], the enzymes responsible for detoxification of a broad spectrum of 
peroxides. cTXN was shown to be essential to trypanosomatids survival [65-67].  
6. Trypanothione directly, or via cTXN, reduces ribonucleotide reductase (RiboR), which is involved in 
DNA synthesis and repair, therefore implicating T(SH)2 in cell division [53]. 
7. A mitochondrial tryparedoxin (mTXN) provides reducing equivalents to the mitochondrial TXNPx 
(mTXNPX) and GPx (mGPx), which is responsible for elimination of reactive oxygen species [50].  
8. Trypanothione, via mTXN, reduces the universal minicircle sequence binding protein (UMSBP), which 
is indispensable for the replication of kDNA [54]. 
9. Trypanothione reduces ascorbate, which serves as substrate of ascrobate peroxidase (AscPX) [68,69]. 
10. Trypanothione is involved in detoxification of xenobiotics via the activity of an S-transferase [51,52], 
oxoaldehydes via the glyoxalase system and also in detoxification of heavy metals [70,71].  
This scheme was adapted from Flohé 2009 [42]. 
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3.3. Trypanothione biosynthesis 
  As mentioned above, T(SH2) is formed by one spermidine and two GSH molecules. 
The metabolic pathways of these two components are similar to those of mammalian cells. In 
the case of GSH, this small thiol is synthesized by the sequential conjugation of cysteine, 
glutamic acid and glycine residues, involving two distinct enzymes, namely glutamate cysteine 
ligase (GCL) and glutathione synthetase. As for spermidine, its biosynthesis starts with L-
arginine conversion to L-ornithine by arginase (ARG), followed by decarboxylation by ornithine 
decarboxilase (ODC) to yield putresine. In parallel, S-adenosylmethionine (AdoMet) is also 
decarboxylated by the S-adenosylmethionine decarboxylase (AdoMetDC) to originate 
decarboxylated AdoMet (dAdoMet). Finally, putresine and dAdoMet are used to generate 
spermidine in a reaction catalyzed by spermidine synthetase (SPDS) [reviewed in 72].  
In trypanosomatids, spermidine and GSH pathways intercept to generate T(SH)2. The 
enzyme responsible for the biosynthesis of this molecule is trypanothione synthetase (TRYS), a 
monomeric enzyme with a molecular weight ranging from 71 kDa in T. brucei to 75 kDa in C. 
fasciculata [73-76]. This enzyme comprises two distinct catalytic domains, a C-terminal 
synthetase domain displaying an ATP-grasp family fold, common to C:N ligases [77,78], and a 
N-terminal amidase domain belonging to the cysteine, histidine-dependent 
amidohydrolase/peptidases (CHAP) superfamily [79]. Trypanothione synthesis is achieved by 
two sequential ATP-dependent conjugations of GSH molecules to spermidine, via a 
mono(glutathionyl)spermidine intermediate. Each conjugation step spends one ATP molecule to 
form a peptide bond between the carboxyl group of the glycine residue of GSH and the N
1
 or the 
N
8
 amino group of spermidine, releasing ADP and orthophosphate, trough a concerted 
substitution mechanism [76]. Importantly, the amidase domain of TRYS is capable of 
hydrolyzing T(SH)2 to restore GSH and spermidine by a nucleophilic attack mechanism, again 
forming mono(glutathionyl)spermidine as intermediate. How these opposing functions are 
regulated to avoid cells to enter in a non-productive ATP consuming futile-cycle is still 
unknown. However, some suggestions have been made that point for an active role of this 
enzyme in the regulation of free polyamine and GSH levels under certain growth conditions 
[80].  
Trypanothione synthetase is present in all members of the Trypanosomatidae family and 
was validated as a drug target in T. brucei [55,56]. However, TRYS exhibits differences within 
this family and sometimes even between species of the same genus. Illustrating this, T. brucei 
synthesizes T(SH)2 as described above with no evidence of other substrate affinity, whereas T. 
cruzi possesses a TRYS capable of accepting spermine and other polyamines as substrate [74]. 
Moreover, it has been reported that C. fasciculata TRYS interacts with other enzyme, the 
glutathionylspermidine synthetase (GSPS) to form a heterodimer. In C. fasciculata, as well as in 
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L. infantum and T. cruzi, GSPS is capable of catalyzing half of the synthesis reaction of TRYS, 
originating the N
1
/N
8
-mono(glutathionyl)spermidine (GSP) intermediate  as a final product 
[74,80,81]. 
 
3.4. Mono(glutathionyl)spermidine biosynthesis 
Glutathionylspermidine synthetase, catalyzes the formation of 
mono(glutathionyl)spermidine by the ATP-consuming conjugation of one molecule of 
spermidine with GSH, through a mechanism similar to that of TRYS [82]. Like TRYS, GSPS 
possesses C-terminal synthetase and N-terminal amidase domains, which are capable of 
synthesizing mono(glutathionyl)spermidine and hydrolyzing both 
mono(glutathionyl)spermidine and T(SH)2 to GSH and spermidine [74,80,83,84]. This enzyme 
was first found in E. coli as a 138 kDa homodimer [85,86] and latter in C. fasciculata  as a 
monomeric 80 kDa protein [80]. The enzyme product is found in all parasites of the 
Trypanosomatidae family, even in species lacking GSPS. This occurrence is attributed to the 
fact that TRYS can generate mono(glutathionyl)spermidine either as a product of incomplete 
T(SH)2 biosynthesis or as a hydrolysis product of T(SH)2 [74-76,80]. Although the functional 
relevance of mono(glutathionyl)spermidine is not completely elucidated, it has been attributed a 
role in cell growth modulation, by regulating polyamines availability [83,87]. Additionally, 
there are some evidences that it can be a substrate for TR and can substitute T(SH)2 in some 
metabolic functions, namely peroxide and ribonucleotide reduction [57-59]. 
 
3.5. Targeting the trypanothione system 
Targeting trypanothione biosynthesis is regarded as a good strategy to fight 
trypanosomatids, not only because many T(SH)2-dependent enzymes have been shown essential 
for parasite survival, as it is also known that many of the currently used trypanocidal drugs exert 
their effect by interfering (directly or indirectly) with the trypanothione system. This is the case 
of eflornithine (DFMO), used to treat sleeping sickness, which inhibits ODC in the early steps 
of spermidine synthesis [88]. Also trivalent arsenicals react directly with T(SH)2, TR or 
tryparedoxin (TXN) leading to the death of parasites [59]. In addition, drugs used to treat 
Chagas’ disease, like nifurtimox or benznidazole, are known to kill parasites by inducing 
oxidative stress that has to be counteracted by the trypanothione-dependent peroxidase system 
[89,90].  
Finding compounds that specifically inhibit pivotal enzymes of this system, like TR or 
TRYS, have been the focus of many rational drug design studies. Several compounds have been 
reported to display good inhibitory effect against recombinant TR of different trypanosomatids 
[91,92]. However, inhibition of this protein to levels that induce parasite death have hardly been 
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accomplished. This fact has been attributed to the need of high inhibition levels of TR activity 
(95%) to impair parasite survival [93,94]. As for TRYS, its inhibition has already been shown to 
impair parasite viability at reasonable drug concentrations. Several classes of compounds have 
been discovered that inhibit TRYS of different trypanosomatids. Recently, paullones, a class of 
compounds used to treat cancer, was discovered to have a potent effect as inhibitor of TRYS 
[95]. Paullones are 7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-ones, a class of ATP 
analogues known to primarily inhibit certain protein kinases, like cyclin-dependent kinases and 
glycogen synthetase kinase-3. Paullones synthesis was described for the first time in 1992 and 
since then has been applied in several medical studies from research in neurosciences to 
apoptosis, diabetes, cancer, embryonic development and anti-parasitic studies [96]. Some 
compounds of this family, namely the group of N
5
-substituted 2-(6-oxo-6,7-dihydro-5H-
benzo[2,3]azepino[4,5-b]indol-5-yl)-acetamides, have proven to be good inhibitors of 
recombinant TRYS of C. fasciculata (IC50=30 nM) and killed T. brucei in culture with an LC50 
near 2 μM (M. Comini, personal communication). Paullones interact with the ATP-binding 
domain of TRYS, causing irreversible inhibition, which is not counteracted by physiological 
concentrations of ATP or any other substrate [95].  
 
4. Aims of the work 
The general aim of this study was to validate the enzymatic pathway for T(SH)2 
biosynthesis as a drug target in L. infantum. As mentioned before, L. infantum harbors a TRYS 
enzyme, which catalyzes both conjugation steps required for T(SH)2 synthesis, as well as GSPS, 
the protein that drives mono(glutathionyl)spermidine formation. So far, the essential role of 
TRYS for parasite survival has only been demonstrated for T. brucei, a trypanosomatid that lacks 
GSPS. In L. infantum, however, it cannot be taken for granted that TRYS is also essential, as 
mono(glutathionyl)spermidine, may replace some of the metabolic functions of T(SH)2. Having 
this in mind, the specific goal of this work was to address the essential role of both TRYS and 
GSPS for L. infantum survival, by employing a reverse genetics strategy. In parallel we have 
also pursued the chemical validation of TRYS using a N
5
-substituted paullone that specifically 
inhibits TRYS activity in vitro. 
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1. Analysis of TRYS and GSPS amino acid sequences 
The L. infantum genome harbors a single copy of the TRYS coding sequence, which is 
predicted to encode a protein (LiTRYS) with 652 amino acids and a molecular mass of 74.23 
kDa. Figure 2.1 shows the predicted amino acid sequence of LiTRYS and compares it to TRYS 
proteins of other trypanosomatids. LiTRYS exhibits 95.2% and 62.1% identity to the formerly 
characterized enzymes of L. major and T. brucei, respectively. Moreover, it shows 78.5% and 
60.5 % identity to TRYS of C. fasciculata and T. cruzi, the species of trypanosomatids that, like 
L. infantum, harbor a GSPS ORF. Trypanothione synthetase of L. infantum shares with 
previously established TRYS a synthetase and amidase domains, and preserves the residues that 
were identified as being important for substrate interaction and/or binding (Figure 2.1) 
[82,84,97]. 
The GSPS of L. infantum is a single copy gene, which encodes a putative protein 
(LiGSPS) with 719 amino acids and a molecular mass of 80.72 kDa. This protein has 70.1% 
identity to the characterized GSPS of C. fasciculata and 49.4% identity to GSPS of T. cruzi. 
Moreover, it possesses both synthetase and amidase domains characteristic of GSPS of other 
organisms. Although LiGSPS shares only 26 % identity with the E. coli GSPS, it preserves the 
main residues that were identified as being important for interactions and/or binding of 
substrates. Interestingly, residues involved in homodimer formation in EcGSPS are not 
conserved in LiGSPS. Instead, LiGSPS possesses several amino acids insertions, which, as 
suggested by Oza et al.[82], may be involved in GSPS interaction with TRYS. Such additional 
residues include a 10 amino acid insertion in the amidase domain, as well as two insertions (of 
14 and 39 amino acids) in the synthetase domain (Figure 2.2). Characterization of both LiGSPS 
and LiTRYS was not carried out in this work, thus the possibility of heterodimer formation by 
these two enzymes remains unexploited in L. infantum.      
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Figure 2.1. Alignment of the predicted amino acid TRYS sequences of different trypanosomatids. 
Protein sequence of TRYS of L. infantum (LiTRYS, accession number A4I2Z3), L. major (LmTRYS, 
accession number AJ311570), C. fasciculata (CfTRYS, accession number AF006615), T. brucei 
(TbTRYS, accession number Q586P2) and T. cruzi (TcTRYS, accession number AF311782) are 
represented. The amidase and synthetase domains are indicated on the left side. Conserved and similar 
residues are highlighted in black background and black frames, respectively. Residues of the linker region 
between domains are underlined. Residues involved in substrates interaction and/or binding are indicated 
by arrow heads: ▲- ATP, ▲- Mg2+, ▲- GSH and ▲-spermidine. Residues involved in amidase activity 
are indicated with ■. 
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Figure 2.2. Alignment of the predicted amino acid GSPS sequences for different organisms. Protein 
sequence of GSPS of L. infantum (LiGSPS, accession number A4I1T8), C. fasciculata (CfGSPS, 
accession number U66520), T. cruzi (TcGSPS, accession number AY828997) and E. coli (EcGSPS, 
accession number U23148) are represented. The amidase and synthetase domains are indicated on the left 
side. Conserved and similar residues are highlighted in black background and black frames, respectively. 
Residues of the linker region between domains are underlined. Residues involved in substrates interaction 
and/or binding are indicated by arrow heads: ▲- ATP, ▲- Mg2+, ▲- GSH and ▲-spermidine. Residues 
involved in amidase activity are indicated with ■. Residues involved in EcGSPS monomer-monomer 
interaction are indicated by ●. 
 
A
m
id
as
e
d
o
m
ai
n
Sy
n
th
et
as
e 
d
o
m
ai
n
Results 
  
 
22 
2. Expression of TRYS along the L. infantum life cycle 
Expression of TRYS was investigated by western blot throughout the life cycle of L. 
infantum, including promastigotes and axenically grown amastigotes. Results, depicted in 
Figure 2.3, show that the enzyme is expressed as a peptide of approximately 75.5 kDa in both 
life cycle stages of the parasite. During promastigote growth expression of TRYS gradually 
increases from the early logarithmic phase to the stationary phase. 
 
  
 
 
 
 
 
 
Figure 2.3. Expression of TRYS during the L. infantum life cycle. Western blot analysis of total 
protein extracts of L. infantum, incubated with an antibody directed against the L. major TRYS. Protein 
extracts from early logarithmic (day 1 of culture or D1) to stationary (day 5 of culture or D5) 
promastigotes were analyzed, as well as from axenically grown amastigotes (A). Ponceau staining of the 
western blot membrane is shown as a control. 
 
3. Genetic validation of TRYS 
Essentiality of TRYS was addressed following a gene replacement strategy. Since L. 
infantum is a diploid organism, two rounds of gene targeting were required to target both TRYS 
alleles. Accordingly, two TRYS replacement constructs were generated. To that end, part of the 
non-coding sequences flanking the TRYS ORF were cloned into two different plasmids, carrying 
either the hygromycin B phosphotransferase gene (HYG), or the phleomycin hydrolase gene 
(PHLEO), which confer resistance to hygromycin B and phleomycin, respectively (Figure 2.4). 
Prior to transfection, these constructs were linearized (by HindIII/SacI double restriction) and 
the replacement cassettes separated from the plasmids backbone.   
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Figure 2.4. Schematic representation of TRYS replacement constructs. The constructs used to target 
TRYS (pGL345-TRYSKØ and pGL726-TRYSKØ) are represented. Hygromycin B phosphotransferase 
(HYG), phleomycin hydrolase (PHLEO), beta-lactamase (AMP) ORFs and 5’, 3’ non-coding sequences 
(5’NCS and 3’NCS) flanking TRYS ORF are represented in boxes. Restriction sites used to assemble the 
constructs are also shown. 
 
3.1. Generation of heterozygous trys::HYG/TRYS L. infantum parasites 
The first TRYS allele was targeted with the HYG replacement cassette. Following the 
transfection procedure, hygromycin-resistant promastigotes were selected and individual clones 
tested by PCR using primers P8 and P9 (see Table 3.1 in the “Material & Methods” section). 
Primer P8 is a sense primer that anneals in the gene upstream of TRYS and was designed to 
diagnose for the correct integration of disruption constructs in the TRYS locus, whereas P9 is an 
anti-sense primer designed to anneal at the beginning of HYG ORF (Figure 2.5 A). Analysis of 
three clones testing positive for the correct integration of the HYG cassette in the TRYS locus is 
shown in Figure 2.5 B. These heterozygous trys::HYG/TRYS mutants (hereafter designated as 
trys
+/-
) presented no differences regarding their morphology (not shown) and growth rate 
(Figure 2.5 C) when compared with wildtype parasites, indicating that one TRYS copy is 
sufficient to sustain promastigote growth in vitro.  
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Figure 2.5. Generation of L. infantum heterozygous trys
+/-
 promastigotes. (A) Representation of the L. 
infantum TRYS locus with its LinJ.27.1780 upstream gene in trys
+/- 
parasites. Both i) wildtype and ii) 
HYG-targeted alleles are shown. The 5’ and 3’ NCS used to construct the HYG replacement cassette are 
represented in grey boxes. Primers P8 and P9 used in the PCR diagnosis for the correct integration of the 
HYG cassette in the TRYS locus are indicated by arrowheads. The number in between arrowheads refers 
to the expected size of the corresponding PCR product. (B) PCR analysis of genomic DNA from three 
hygromycin-resistant mutants (clones 1, 2 and 6) and wildtype parasites, using primers P8 and P9. (C) 
Growth curves of wildtype (WT) and trys
+/-
 (clone 1) promastigotes. Parasites were seeded at 10
6
 at day 0 
and counted daily with a hemocytometer. Data represent the mean and standard deviation of two 
independent growth curves. 
 
3.2. Attempts to generate L. infantum TRYS null mutants 
In order to replace the second TRYS allele, the trys
+/-
 clone 1 was selected for 
transfection with the PHLEO replacement cassette. Following the transfection procedure, 
parasites resistant to both hygromycin and phleomycin were selected and three individual clones 
analyzed by PCR to diagnose for different events, namely (see Figure 2.6 A): i) integration of 
the PHLEO cassette into the TRYS locus; ii) presence of the PHLEO, HYG and TRYS ORFs; iii) 
maintenance of the HYG cassette in its correct position and iv) configuration of the endogenous 
TRYS locus. The results, depicted in Figure 2.6 B, show that none of the clones tested positive 
for the correct integration of the PHLEO cassette in the TRYS locus. Still, the PHLEO ORF was 
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amplified, at least in clones 3 and 5. The HYG ORF was kept in its correct location in the TRYS 
locus during the second transfection procedure. Importantly, all three clones retained the TRYS 
ORF, in its original locus (clones 3 and 5) or possibly in other position of the genome (clone 1). 
The failure to eliminate both gene alleles of TRYS is per se suggestive that this may be an 
essential gene [31]. 
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Figure 2.6. Leishmania infantum parasites obtained upon the second round transfection with the 
PHLEO replacement cassette. (A) Representation of the L. infantum TRYS locus with its LinJ.27.1780 
upstream gene in i) the wildtype allele and as expected upon the recombination events with the ii) HYG 
and iii) PHLEO integration cassetes. The 5’ and 3’ NCS used to construct the HYG and PHLEO 
replacement cassettes are represented in grey boxes. Primers used in the PCR diagnosis for the different 
integration events in the TRYS locus, as well as to amplify the TRYS, HYG and PHLEO ORFs are 
indicated by arrowheads. Numbers in between arrowheads refer to the expected size of the corresponding 
PCR products. (B) PCR analysis of genomic DNA from three hygromycin- and phleomycin-resistant 
mutants (clones 1, 3 and 5). Primers used in the PCR reactions are indicated in parenthesis. The same 
reactions were carried out in the absence of DNA to serve as negative control (C -). 
 
3.3. Generation of L. infantum TRYS null mutants requires previous complementation with 
episomic TRYS 
Following two sequential rounds of transfection we were not able to eliminate both 
TRYS alleles, suggesting that this gene might be essential to promastigote survival. To rule out 
the possibility that technical limitations could be hindering the isolation of TRYS-depleted 
TRYSLinJ.27.1780
5’ NCS 3’ NCS
P27P8
P6P5
1000 bp
1950 bp
HYGLinJ.27.1780
5’ NCS 3’ NCS
P9P8
P12P11
1000 bp
1050 bp
LinJ.27.1780
5’ NCS 3’ NCS
PHLEO
P14
P10P8
P13
1000 bp
380
i) 
ii) 
iii) 
7 
Results 
  
 
26 
Episomic TRYS (P25/P6)
HYG integration (P8/P9)
C
lo
n
e
  3
C
lo
n
e
  8
C
lo
n
e
  1
0
W
ild
 ty
p
e
C
+
600bp
2900 bp
1000 bp
2500 bp
pTEX R1 (P5/P10)
pTEX R2 (P23/P26)
Episomic TRYS (P25/P6)
HYG integration (P8/P9)
C
lo
n
e
  3
C
lo
n
e
  8
C
lo
n
e
  1
0
W
ild
 ty
p
e
C
+
600bp
2900 bp
1000 bp
2500 bp
pTEX R  (P5/P10)
pTEX R2 (P23/P26)
TRYS NEO
AMP
pTEX-NEO-TRYS
2900 bp
P10P5
P26P23P6P25
600 bp2500 bp
parasites, we followed another experimental approach. This consisted in introducing an 
episomal copy of the TRYS gene into trys
+/-
 mutants prior to transfection with the PHLEO 
replacement cassette. To that end the trys
+/-
 clone 1 was transfected with the trypanosomatidal 
expression vector pTEX-NEO carrying the TRYS ORF (Figure 2.7 A). This vector carries the 
neomycin phosphotransferase gene (NEO), which confers resistence to geneticin. Following the 
transfection procedure, three hygromycin- and geneticin-resistant clones were confirmed by 
PCR (Figure 2.7 B) to carry an episomal copy of TRYS (P25/P6), as well as to preserve the HYG 
ORF in its the correct location in the TRYS locus (P8/P9). One of the clones (clone 8) was 
further tested for the integrity of the episome using different combinations of primers (P5/P10 
and P23/P26). The results, depicted in Figure 2.7 B, indicated that the pTEX-NEO-TRYS 
episome was intact in this clone. These trys
+/-
 parasites carrying an extrachromosomal copy of 
TRYS were subsequently used for the second round of targeting of the TRYS locus with the 
PHLEO cassette. The outcome of this transfection was the isolation of parasites resistant to 
hygromycin, geneticin and phleomycin. Southern blot analysis of three of these clones 
confirmed the successful replacement of both TRYS alleles. Illustrating this, the 4.9 kb band, 
which corresponds to the chromosomal TRYS copy in SacII-digested DNA (Figure 2.8 A), was 
not detected in any of these mutants (Figure 2.8 B). Instead, a 7.6 kb band, matching the 
episomal TRYS copy, was recognized by the TRYS probe. This 7.6 kb fragment also hybridized 
to the NEO probe, further confirming the presence of the TRYS episome. Integrity of both HYG- 
and PHLEO-targeted alleles was verified using the corresponding radiolabeled-ORFs as probes. 
As shown in Figure 2.8 B, the HYG probe labeled one band of approximately 2 kb, which likely 
contains the 1.9 and 2.1 kb fragments that result from SacII restriction of the HYG allele (Figure 
2.8 A). As for the PHLEO probe, it detected a 3.3 kb band, as expected for the correct 
integration of the PHLEO cassette into the TRYS locus. These Δtrys::HYG/Δtrys::PHLEO 
[pTEX-NEO-TRYS] mutants will be from here on be designated as trys
-/-
/+TRYS. 
                   
 
 
 
 
Figure 2.7. Analysis of pTEX-NEO-TRYS complemented trys
+/-
 mutants. (A) Schematic 
representation of the pTEX-NEO-TRYS plasmid. Trypanothione synthetase (TRYS), neomycin 
phosphotransferase (NEO) and beta-lactamase (AMP) ORFs are represented in boxes. Primers used in the 
PCR analysis in (B) are indicated by arrowheads. Numbers in between arrowheads refer to the expected 
size of the corresponding PCR products. (B) PCR analysis of genomic DNA from three independent 
pTEX-NEO-TRYS complemented trys
+/-
 mutants (clones 3, 8 and 10) and wildtype promastigotes. 
Purified pTEX-NEO-TRYS plasmid was used as template to serve as positive control in some of the 
reactions (C +). Primers used in the PCR reactions are indicated in parenthesis and their location is 
represented in (A), except for primers P8 and P9, whose binding site is depicted in Figure 2.6. 
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Figure 2.8. Southern blot analysis of trys
-/-
/+TRYS mutants. (A) Representation of the L. infantum 
TRYS locus with its LinJ.27.1780 upstream gene i) before and after TRYS replecement by the ii) HYG and 
iii) PHLEO cassettes. iv) Also depicted is the scheme of the pTEX-NEO-TRYS episome. Sizes of the 
predicted SacII-restriction fragments are indicated. (B) Southern blot of SacII-digested genomic DNA of 
wildtype and three trys
-/-
/+TRYS mutants (clones 3, 4 and 5) hybridized with radiolabeled NEO, TRYS, 
HYG and PHLEO ORFs. 
 
3.4 Maintenance of the pTEX-NEO-TRYS episome in the absence of drug pressure confirms 
gene essentiality in promastigotes 
 Leishmania episomes are highly unstable and are usually lost over time unless they 
provide an advantage to the parasite. The pTEX-NEO vector used to introduce the TRYS 
episomal copy is no exception to this and, as such, it is lost when parasites are cultured in the 
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absence of geneticin [98]. To otain definitive proof of TRYS essentiality, we used this feature of 
pTEX-NEO and cultured trys
-/-
/+TRYS promastigotes for 6 months in absence of geneticin. The 
maintenance of the vector was tested in two independent clones by Southern blot and by a 
geneticin-resistance assay.  
 Southern blot analysis revealed that both clones retained the pTEX-NEO-TRYS plasmid. 
As depicted in Figure 2.9 A, hybridization of SacII-digested genomic DNAs of the trys
-/-
/+TRYS 
mutants with either the radiolabeled NEO or TRYS ORFs yielded a band of approximately 7.6 
kb, corresponding to the pTEX-NEO-TRYS plasmid. Control for the lost of plasmid was 
performed in parallel using wildtype parasites carrying the empty pTEX-NEO vector. Three 
months in the absence of geneticin were enough for these parasites to lose the plasmid, as 
evidenced by disappearance of the 5.6 kb SacII-fragments hybridized to the NEO probe in 
parasites cultured in the absence of the drug. 
 Results obtained in the geneticin-resistance assays were in line with the Southern blot 
analysis. As shown in Figure 2.9 B, control parasites cultured in the absence of G418 had lost 
resistance to this drug, contrary to control parasites that were cultured in parallel in the presence 
of drug pressure. Both trys
-/-
/+TRYS clones cultured in the absence of G418 were resistant to 
this drug, indicating that they preserved the pTEX-NEO-TRYS plasmid. 
 Altogether the results presented here show that in the absence of drug pressure the 
episomal copy of TRYS is not lost in parasites lacking the endogenous gene. Requirement for 
TRYS likely provides the pressure to maintain the episome, thus implying that this gene is 
essential for promastigote survival.  
A                               B 
 
 
 
 
 
 
 
 
 
Figure 2.9. Southern blot analysis of trys
-/-
/+TRYS mutants cultured in the absence of geneticin. (A) 
Southern blot of SacII-digested genomic DNA of two trys
-/-
/+TRYS mutants (Clones 3 and 4) cultured for 
6 months in the absence of geneticin and of control parasites (pTEX-NEO) cultured for 3 months either in 
the absence (-G418) or in the presence  of 40 µg ml
-1
 of geneticin (+G418). Blots were hybridized with 
radiolabeled NEO and TRYS ORFs. (B) Effect of geneticin on the survival of trys
-/-
/+TRYS mutants 
(clones 3 and 4) that had been cultured for 6 months in the absence of drug pressure. Control parasites are 
wildtype (WT) and pTEX-NEO transfectants [grown for 3 months either in the absence (-G418) or 
presence (+G418) of geneticin]. Four to seven days after the addition of G418, the number of 
promastigotes was counted with a hemocytometer and the data expressed as the percentage of parasite 
number in cultures to which no drug had been added. Data refers to one experience. 
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3.6. Assessment of TRYS essentiality in the amastigote stage of L. infantum 
 For a gene to be validated as a drug target, it has to be proven essential in the 
mammalian stage of the parasite. To assess TRYS essentiality in amastigotes, BALB/c mice 
were inoculated with three trys
+/-
/+TRYS clones and with pTEX-NEO control parasites. Nine 
weeks after infection, control parasites were recovered from the liver and spleen of infected 
mice and analyzed for the presence of the pTEX-NEO plasmid by PCR and by a geneticin-
resistance assay. Both experimental approaches revealed that these parasites retained the 
plasmid upon 9 weeks in mice. As such, analysis of the trys
+/-
/+TRYS clones was not performed 
at this time point and will have to await at least 4 additional weeks, as to guarantee loss of 
pTEX-NEO by the control parasites [67].  
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Figure 2.10. Analysis of pTEX-NEO transfected parasites recovered from mice 9 weeks after 
infection. (A) PCR analysis of genomic DNA from control parasites (pTEX-NEO) recovered from the 
liver and spleen of BALB/c mice 9 weeks after infection. Purified pTEX-NEO-TRYS plasmid was used as 
template in the positive control reaction (C +). Primers used in the PCR reactions are indicated in 
parenthesis. (B) Effect of geneticin on the survival of control parasites (pTEX-NEO) recovered from the 
liver and spleen of BALB/c mice 9 weeks post infection. Four days after the addition of G418, the 
number of promastigotes was counted with a hemocytometer and the data expressed as the percentage of 
parasite number in cultures to which no drug had been added. Data represent counts from one experience. 
Wildtype parasites were used as control in both (A) and (B).  
 
4. Chemical validation of TRYS 
4.1. Preliminary assays 
To chemically validate a gene, one must first identify compounds that specifically 
inhibit the product of that gene. The N
5
-substituted paullones were identified by our German 
partner (at MOLISA, GmbH) as potent inhibitors of purified recombinant L. infantum TRYS 
with IC50 values in the nanomolar range (Table 2.1). These compounds were therefore chosen to 
carry out the chemical validation of LiTRYS.  
From the existing set of compounds, we chose four that exhibited the highest LiTRYS 
inhibitory effect in vitro, namely FS-304, FS-554, FS-528 and FS-99a. The leishmanicidal 
effect of these compounds was tested at 5 and 50 µM against intracellular L. infantum 
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amastigotes residing in monolayers of murine peritoneal macrophages. Upon incubation with 
drugs, cells were stained for immunofluorescence analysis. Micrographs representative of this 
experiment are shown in Figure 2.11. As revealed from alterations on cell morphology, three of 
these drugs (FS-304, FS-528 and FS-99a) were toxic to macrophages at 50 µM. Moreover, at 
the other concentration tested (5 µM), these compounds had no apparent anti-parasitic effect, as 
indicated by the high load of intracellular amastigotes. On the contrary, FS-554 did not 
significantly affected macrophages morphology at 50 µM and reduced the number of 
intracellular amastigotes at both concentrations tested (Figure 2.11).  
Before quantifying the effect of FS-554 on amastigote survival, we performed a viability 
assay to access toxicity of this drug towards macrophages. To that end, non-infected 
macrophages were incubated with increasing concentrations of FS-554 and their viability 
measured by the resazurin assay. Results showed a marked decrease in cell viability for 
concentrations above 30 µM (1.5 log units in Figure 2.12 A). As such, the anti-parasitic effect 
of the compound was only assessed at 5 µM, although the microscopic observation of the 
monolayers at 50 µM indicates a near 100 % reduction of infection (Figure 2.11). Quantification 
of the leishmanicidal effect of FS-554 at 5 µM revealed a 2.25 fold reduction in the infection 
index (Figure 2.12 B).        
To discard the possibility that the observed leishmanicidal effect of FS-554 could result 
from activation of macrophages, we employed the Griess assay to measure the amount of nitrite 
(NO2
-
), a microbicidal molecule that is generated by activated macrophages [10]. Formation of 
NO2
-
 was measured in the supernatant of infected and non-infected macrophages cultured in the 
presence of increasing amounts of FS-554. Results revealed that, in all tested conditions, the 
amount of NO2
-
 was undetectable, thus indicating that the anti-parasitic effect of FS-554 was 
not the consequence of macrophage activation (data not shown).  
Altogether, these results indicate that FS-554 is an appropriate compound to be used in 
the chemical validation of TRYS in both L. infantum life cycle stages.  
 
Table 2.1. List of N
5
-substituted paullones and their IC50 values against purified 
recombinant L. infantum TRYS. 
 
  
Code IC50 (nM) 
FS-304 31,2 
FS-554 52 
FS-528 208 
FS-99a 235 
FS-202 295 
FS-586 319 
FS-573 469 
FS-185 537 
FS-634 785 
FS-151 837 
FS-628 951 
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Figure 2.11. Preliminary screening of N
5
-substituted paullones on intracellular L. infantum 
amastigotes. Representative IFAT micrographs of each tested compound at 5 and 50 µM. Nucleus of 
macrophages are marked with DAPI (shown in red) and amastigotes are labeled with primary antibodies 
anti-LicTXNPx1 and anti-LimTXNPx (shown in green).  
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Figure 2.12. Cytotoxic effect of FS-554 on macrophages and intramacrophagic L. infantum 
amastigotes. (A) Effect of FS-554 on the viability of murine peritoneal macrophages. Macrophages were 
incubated with different concentrations of FS-554 (0 to 250 µM) and viability addressed by the resazurin 
assay. Data are expressed as a percentage of cell viability relative to macrophages to which no FS-554 
was added. (B) Effect of FS-554 against intracellular amastigotes. Infection index of monolayers of L. 
infantum-parasitized murine peritoneal macrophages upon treatment with 5 µM FS-554 for 48 hours. 
Data in (A) and (B) represent means and standard deviations of triplicate measurements from one 
experience.   
 
4.2. TRYS expression levels correlate with resistance of L. infantum to FS-554  
Chemical validation of TRYS was addressed by evaluating the potency of FS-554 against 
parasites expressing different levels of the enzyme. To that end, we made use of the previously 
produced heterozygous trys
+/-
 mutants, as low TRYS-expressing parasites, and addionally 
transfected wildtype promastigotes with the pTEX-NEO-TRYS plasmid to obtain TRYS 
overexpressers. Correct genotypes of these transfectants were confirmed by Southern blot 
(Figure 2.13 A). The expression levels of TRYS were kept high by addition of geneticin to the 
cultures, which guarantees the maintenance of several copies of the plasmid, hence of episomic 
TRYS. Wildtype parasites transfected with pTEX-NEO were used as a control of the TRYS 
overexpressers, in order to evade effects of geneticin in the parasite growth. Of notice, the 
TRYS overexpressers did not show any differences regarding morphology (not shown) and 
growth rate (Figure 2.13 B) with respect to control parasites. 
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Figure 2.13. Analysis of TRYS overexpressers. (A) Southern blot analysis of TRYS overexpressers 
parasites. Hybridization of SacII-digested DNA from TRYS overexpressers with the radiolabeled TRYS 
ORF, yielded a 7.6 kb band corresponding to the pTEX-NEO-TRYS plasmid. Please notice that the 4.9 kb 
band corresponding to the endogenous TRYS locus is not detected in these mutants, possibly due to 
technical limitations. (B) Growth curves of control parasites (pTEX-NEO) and TRYS overexpressers in 
the presence of 40 µg ml
-1
 geneticin.  Promastigotes were seeded at 10
6
 at day 0 and counted daily with a 
hemocytometer. Data represent means and standard deviations of two independent growth curves. 
 
 
 The leishmanicidal effect of FS-554 was subsquently tested towards promastigotes 
expressing different levels of TRYS. Relative amounts of TRYS in wildtype, trys
+/-
, TRYS 
overexpressers and control parasites were verified by western blot (Figure 2.14 A). The results, 
depicted in Figure 2.14 B, show that parasites with decreased TRYS expression are more 
sensitive to FS-554, while overexpression of the protein confers promastigotes resistance to this 
drug. Non-linear fit of this data was performed, allowing us to determine the EC50 of FS-554 
towards each parasite line (Table 2.2). 
  
A                                                                    B 
 
 
 
 
 
 
 
Figure 2.14. Correlation between TRYS expression levels and susceptibility of L. infantum 
promastigotes to FS-554. (A) Western blot analysis of total protein extracts from previous synchornized 
cultures of wildtype, homozygous trys
+/-
, pTEX-NEO and TRYS overexpressers, incubated with an 
antibody directed against the L. major TRYS. Sypro Ruby
®
 staining of the western blot membrane is 
shown as a control.  (B) The same parasite lines were tested for their viability upon incubation with 
increasing concentrations of FS-554 (0 to 250 µM). Promastigotes were seeded at 10
6
 cell ml
-1
 and 
incubated with the drug for 48 h. Cell viability was determined by the resazurin assay after 24-96 h upon 
the addition of resazurin. Data represent means and standard deviations of triplicate measurements from 
three independent experiences. Curves are the non-linear fit of the data, obtained using a two-parameter 
EC50 equation provided by Graphpad prism 5 software. 
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Table 2.2. EC50 values of FS-554 against promastigotes expressing different levels of 
TRYS. 
 
 
 
 
 
  
 The relative susceptibility of wildtype and trys
+/-
 mutants to FS-554 was also addressed 
in intramacrophagic amastigotes. In line with the results obtained with promastigotes, trys
+/-
 
were more susceptible to FS-554 than wildtype parasites, as deduced from the infection indexes 
of macrophages treated with this drug. As depicted in Figure 2.15, at 15 µM FS-554 the 
infection index of trys
+/-
 parasites decreased 1.5 fold, while having no effect on wildtype cells. 
Likewise, at 30 µM the effect of FS-554 was also more pronounced towards trys
+/-
  (a 2.5 fold 
reduction in infection index), than towards wildtype L. infantum amastigotes (1.7 fold reduction 
in infection index).  
 Together these results strongly suggest that the L. infantum TRYS is targeted by FS-554 
in both the promastigote and the amastigote stages, in other words, that it is prone to 
inactivation with drug-like compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15. Effect of FS-554 on survival of intramacrophagic L. infantum amastigotes expressing 
different levels of TRYS. Infection indexes of wildtype (WT) and heterozygous trys
+/-
 amastigotes at 0, 
15 and 30 µM of FS-554. Data represent means and standard deviations of triplicate measurements from 
one experience. 
 
5. GSPS functional characterization   
Functional characterization of GSPS was performed following the same rationale 
described for TRYS genetic validation. Accordingly, two replacement constructs were generated 
by cloning part of the 5’ NCS and 3’NCS flanking the GSPS ORF into two different plasmids, 
carrying either the blasticidin S deaminase (BSD) gene or the puromycin N-acetyl-tranferase 
(PAC) gene, which confer resistance to blasticidin or puromycin, respectively. Prior to 
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transfection, these constructs were linearized (by HindIII/BglII double restriction) and the 
plasmid backbone rejected (Figure 2.16). 
 
 
 
 
   
 
 
Figure 2.16. Schematic representation of GSPS replacement constructs. Constructs used to target 
GSPS (pGL434-GSPSKØ and pGL701-GSPSSKØ), are represented. Blasticidin S deaminase (BSD), 
puromycin N-acetyl-tranferase (PAC), beta-lactamase (AMP) ORFs and 5’ and 3’ non-coding 
sequences (5’NCS and 3’NCS) flanking the GSPS ORF are represented in boxes. Restriction sites used to 
assemble constructs are also shown. 
5.1. Generation of L. infantum heterozygous gsps::BSD/GSPS parasites 
In order to obtain heterozygous GSPS parasites, the first GSPS allele was targeted with 
the BSD replacement cassette. Following the transfection procedure, blasticidin-resistant 
promastigotes were selected and individual clones tested by PCR using primers P19, P20 and 
P22 (see Table 3.1 in “Matherial & Methods”). Primer P19 is a sense primer designed to anneal 
in the gene upstream of GSPS (LinJ.25.2490), thus allowing the diagnosis for the correct 
integration of the disruption constructs in the GSPS locus. Primers P20 and P22 are anti-sense 
primers designed to anneal at the beginning of the BSD and the GSPS ORFs, respectively 
(Figure 2.17 A). The result of the PCR analysis of one clone testing positive for the correct 
integration of the BSD cassette in the GSPS locus, as well as for the maintainance of one GSPS 
allele, is shown in Figure 2.17 B. This heterozygous gsps::BSD/GSPS mutant (hereafter 
designated as gsps
+/-
) presented no morphologic alterations in comparison to wildtype 
promastigotes (not shown). 
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Figure 2.17. Generation of heterozygous gsps
+/-
 promastigotes. (A) Representation of the L. infantum 
GSPS locus with its LinJ.25.2490 upstream gene in gsps
+/- 
parasites. Both i) wildtype and ii) BSD-
targeted alleles are shown. The 5’ and 3’ NCS used to construct the BSD replacement cassette are 
represented in grey boxes. Primers used in PCR diagnosis for the correct integration of the BSD cassette 
in the GSPS locus are indicated by arrowheads. The number in between arrowheads refers to the expected 
size of the corresponding PCR product. (B) PCR analysis of genomic DNA from one blasticidin-resistant 
mutant (clone 6) and wildtype promastigotes, using the primers indicated in parenthesis. 
 
5.2. Attempts to generate L. infantum GSPS null mutants  
Targeting of the second GSPS allele was performed in the gsps
+/-
 clone 6 with the PAC 
replacement cassette. Following the transfection procedure, parasites resistant to both blasticidin 
and puromycin were selected and the polyclonal culture analyzed by PCR to diagnose for 
different events, namely: i) integration of the PAC cassette into the GSPS locus; ii) maintenance 
of the BSD cassette in its correct position and iii) preservation of the endogenous GSPS locus 
(see figure 2.18 A). Results indicate that the polyclonal population tested positive for all three 
events. This is possibly due to the presence of genomic DNA from different clones serving as 
templates in the PCR reactions. Efforts are being made to isolate individual clones and to 
conclude about GSPS essentiality in L. infantum. 
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Figure 2.18. L. infantum parasites obtained upon the second round of transfection to target the 
GSPS locus with the PAC replacement cassette. (A) Representation of the L. infantum GSPS locus with 
its LinJ.25.2490 upstream gene in i) the wildtype allele and as expected upon the recombination events 
with the ii) BSD and iii) PAC integration cassetes. The 5’ and 3’ NCS used to construct the BSD and PAC 
replacement cassettes are represented in grey boxes. Primers used in the PCR diagnosis for the different 
integration events in the GSPS locus are indicated by arrowheads. Numbers in between arrowheads refer 
to the expected size of the corresponding PCR products. (B) PCR analysis of genomic DNA from 
blasticidin- and puromycin-resistant polyclonal culture (gsps
-/-
) and wildtype promastigotes. Primers used 
in PCR reactions are indicated in parenthesis. The same reactions were carried out in the absence of DNA 
to serve as negative control (C -). 
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1. General considerations 
At present, chemotherapies used to treat visceral leishmaniasis are unsatisfactory. The 
quest for new molecules that efficiently induce parasite death is tightly correlated with the 
finding of new molecular targets that can be inhibited inside the host without undesired cross-
reactivity. The thiol system of trypanosomatids is different from that of their mammalian hosts 
and has long been considered as a potential site for inhibition with specific drugs. This system 
largely depends on trypanothione, a unique dithiol that, directly or indirectly, supplies reducing 
equivalents to a myriad of enzymes, many of which have been proven essential for 
trypanosomatid survival. Therefore, targeting the enzyme responsible for the synthesis of 
trypanothione has been suggested as an adequate strategy to interfere with the thiol system of 
trypanosomatids, hence with parasite viability. Trypanothione synthetase is an exclusive, unique 
in sequence, low abundance protein that has been proven essential to T. brucei. However, this 
parasite lacks GSPS and, as such, the possibility of compensatory mechanisms involving 
mono(glutathionyl)spermidine remains unexploited in trypanosomatids. Validation of TRYS as a 
drug target in organisms harboring GSPS, such as L. infantum, has not been reported so far. The 
work carried out in the course of this Msc work focused on the dissection of the functional 
relevance of TRYS and GSPS in L. infantum. Our main findings and conclusions are discussed 
bellow. 
 
2. TRYS is essential during the insect stage of L. infantum 
Genetic validation of TRYS by homolougous recombination proved that this gene is 
essential to L. infantum promastigotes, hence that mono(glutathionyl)spermidine alone cannot 
sustain all trypanothione-dependent functions. The first indication for TRYS essentiality came 
from our failure to generate homozygous knockout parasites. Indeed, the double targeted HYG 
and PHLEO transfectants, in addition to carrying both drug resistant markers, preserved the 
TRYS ORF. Although we did not explore this further, the presence of all three genes in these 
mutants may have occurred either by formation of extrachromosomal amplicons or by 
chromosome duplication, two strategies that are usually employed by Leishmania to avoid 
depletion of essential genes [31]. Elimination of both TRYS alleles was only possible upon 
complementation of heterozygous trys
+/-
 mutants with an episomal copy of the gene. Definitive 
proof for TRYS essentiality was obtained from the observation that these pTEX-NEO-TRYS-
complemented trys
-/-
 promastigotes did not lose the plasmid even upon being cultured for 6 
months in the absence of geneticin. In these transfectants the pressure to maintain the pTEX-
NEO plasmid was provided by the requirement for the episomal TRYS gene during promastigote 
growth, thus proving that this is a crucial gene [67]. To assess TRYS essentiality in amastigotes 
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residing in mammalian hosts we employed an identical strategy. This experiment is still 
underway, but based on our finding that intramacrophagic L. infantum amastigotes are 
susceptible to FS-554, a potent inhibitor of TRYS in vitro, we expect this protein to be non-
redundant in the amastigote stage as well. 
 
3. LiTRYS can be targeted by drug-like compounds in the cell context 
The chemical validation of TRYS was also pursued in this work using FS-554, a potent 
inhibitor of TRYS activity in vitro that belongs to the family of N
5
-substituted paullones [95]. 
Assays performed on both promastigotes and intramacrophagic amastigotes revealed that TRYS 
expression levels consistently correlated with L. infantum resistance to FS-554. These 
observations strongly suggest that TRYS can be targeted in the cell context by drug-like 
compounds. From the rational drug design standpoint this is an important result as it evidences 
the possibility of designing drugs that can be internalized by parasites (as well as by 
macrophages) and bind TRYS. However, from our observations we cannot safely conclude that 
FS-554-induced parasite death is a consequence of TRYS inactivation. In fact, being aware that 
paullones interact promiscuously with most ATP-binding proteins [96], it may happen that FS-
554 also inhibits other targets (e.g. GSPS, kinases) that are vital to the parasite. Following this 
rationale, overexpression of TRYS would prevent FS-554 from binding and inhibiting other 
potentially vital targets. One way to elucidate the inhibitory effect that FS-554 actually exerts 
over TRYS in the cell context involves the quantification of trypanothione (as well as other 
small thiols) in FS-554-treated L. infantum promastigotes. 
 
4. What is the functional relevance of GSPS? 
The presence, in some trypanosomatids, of a GSPS sequence is regarded as a trace of a 
common ancestor that is being lost throughout evolution. Supporting this idea is the fact that 
TRYS per se is capable of synthesizing trypanothione in vitro. Moreover, L. major carries a 
GSPS pseudogene that has been suggested to represent the evolutionary link between 
trypanosomatids that harbor both enzymes and those that possess only TRYS [75]. Despite these 
considerations, the relevance of GSPS in these organisms remains unaddressed, and this was the 
reason why we pursued the functional characterization of this protein in L. infantum. Upon the 
first attempt to generate gsps
-/-
 knockouts, and while awaiting the outcome of this experiment, 
we can only speculate about the possible scenarios regarding GSPS essentiality. First, our 
results may indicate that GSPS is redundant throughout the L. infantum life cycle, and as such, 
confirm previous suggestions that this gene is to be lost throughout parasite evolution. Second, 
the enzyme may be found essential at least in one life cycle stage of the parasite. On the basis of 
  Disscusion 
43 
our current knowledge that TRYS is an essential enzyme or, in other words, that no other thiol 
can replace trypanothione, the functional relevance of GSPS cannot be attributed to its 
mono(glutathionyl)spermidine biosynthetic activity. Alternatively, an essential role for GSPS 
may be attributed to its putative ability to interact and form a functional complex with TRYS. In 
fact, as suggested by Oza et al. [82], in organisms expressing both proteins, GSPS, which is a 
homodimeric enzyme in E. coli, may associate with TRYS via several amino acid extensions 
that are absent in the prokaryotic enzyme. Formation of a functional TRYS-GSPS complex in 
vivo has so far been reported in C. fasciculata [99] and has not yet been addressed in other 
trypanosomatids harboring GSPS. In the future, if GSPS is found to be crucial for L. infantum 
survival, the heteromeric nature of TRYS and GSPS, as well as the influence that such putative 
complex has on the enzymatic activity of both proteins, will be investigated. 
 
5. Final remarks 
The work presented in this MSc thesis represents, to our knowledge, the first study of 
TRYS essentiality in a trypanosomatid harboring both TRYS and GSPS sequences. The results 
gathered here demonstrate that, at least in the promastigote stage of L. infantum, i) TRYS is 
crucial to ensure parasite survival and ii) as such, its functions cannot be replaced by GSPS. 
Work is on going to elucidate whether these observations also apply to the mammalian stage of 
L. infantum. In addition to these results, evidence is also provided that TRYS is a druggable 
target, i.e. it is prone to inactivation by drug-like compounds, a requisite for target validation. 
Finally, we also report on the production of GSPS knockouts, which will be used in future work 
to assess the functional relevance of this gene in L. infantum. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
Chapter 4 
 
Material & Methods 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Materials & Methods 
 
47 
1. Parasite cultures 
Leishmania infantum promastigotes (strain MHOM/MA/67/ITMAP-263) were cultured 
in RPMI 1640 Glutamax medium supplemented with 10% (v/v) heat inactivated fetal bovine 
serum (FBSi), 50 U ml
-1
 penicillin, 50 µg ml
-1
 streptomycin and 20 mM Hepes sodium salt pH 
7.4 (complete medium) at 25 ºC. Axenic amastigotes of the same strain were grown at 37 ºC in 
MAA medium supplemented with 20% FBSi, 2 mM glutamax (GibcoBRL
®
), 0.023 mM hemin 
as described previously [67]. When required, promastigote cultures were synchronized by 3–4 
daily passages of 10
6
 cells ml
−1
. To obtain parasites at different stages of growth, cultures were 
seeded at 10
6
 cells ml
−1
 and harvested daily from day 1 to day 6. 
2. Primers 
All primers used in this work to generate DNA constructs and/or to diagnose for their 
correct assembly and integration in the L. infantum genome are summarized in Table 4.1. 
Primers were purchased from Sigma-Alrdich
®
 as non-modified, desalted oligonucleotids.  
Table 4.1. List of oligonucleotides employed in this work. Clamp sequences are indicated in 
lower case and restriction sites underlined. 
Primer name Primer sequence Function 
P1 cccaagcttCTATATATGTGTCTCACTGC Sense primer to amplify  5'NCS flanking LiTRYS ORF  
P2 ggactagtGGCTTATGATTGCTGTGTG Anti-sense primer to amplify 5'NCS flanking LiTRYS ORF 
P3 cgcggatccCGTCCGGGCTGCAAGC Sense primer to amplify  3'NCS flaking LiTRYS ORF 
P4 cgcgagctcTGCTGCGCAATACACACAA Anti-sense primer to amplify 3'NCS flaking LiTRYS ORF 
P5 ccgcgcacatATGTCGTCTCTGCCG CG Sense primer to amplify LiTRYS ORF 
P6 caccgctcgagTTACTCGTCCTCGGCCAT Anti-sense primer to amplify LiTRYS ORF 
P7 CGCGGCAGAGACGACAT Anti-sense primer at the beginning of TRYS ORF 
P8 TCGTTGCTGGAGTACGATG Sense primer to confirm correct integration LiTRYS replacement 
cassettes (gene upstream of LiTRYS ORF) 
P9 CGCGGTGAGTTCAGGCTT Anti-sense primer to confirm correct integration of HYG cassette 
(beginning of HYG ORF) 
P10 CACTGGTCAACTTGGCCAT Anti-sense primer to confirm correct integration of PHLEO cassette 
(beginning of PHLEO ORF) 
P11 AAGCCTGAACTCACCGCG Sense primer to amplify HYG ORF 
P12 CTATTCCTTTGCCCTCGGA Anti-sense primer to amplify HYG ORF 
P13 ggactagtATGGCCAAGTTGACCAGTGC Sense primer to amplify PHLEO ORF 
P14 ggactagtTCAGTCCTGCTCCTCGGC Anti-sense primer to amplify PHLEO ORF 
P15 cccaagcttGCTACACATCAGCTGATGA Sense primer to amplify  5'NCS flanking LiGSPS ORF 
P16 cggactagtGAGCGTTTTTCGTAGCCG Anti-sense primer to amplify 5'NCS flanking LiGSPS ORF 
P17 cgcggatccCTCTCACCCTCGCTGTG Sense primer to amplify  3'NCS flanking LiGSPS ORF 
P18 gggagatctTGTGCGGTGCTGCAGGT Anti-sense primer to amplify 3'NCS flanking LiGSPS ORF 
P19 AAATCGTTCTGAGCGAGTAG Sense primer to confirm correct integration of LiGSPS replacement 
cassettes (gene upstream of LiGSPS)  
P20 CGCTGGCGACGCTGTAG Anti-sense primer to confirm correct integration of BSD cassette 
P21 TGGGCTTGTACTCGGTCAT Anti-sense primer to confirm correct integration of PAC cassette 
P22 GCGTGGCAGAGACAGCAT Anti-sense primer at the beginning of GSPS ORF 
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P23 CTTGACGAGTTCTTCTGA Sense primer to verify pTEX-TRYS integrity (end of NEO ORF) 
P24 TTCAATGGCCGATCCCAT Anti-sense primer to verify pTEX-TRYS integrity (beginning of NEO ORF) 
P25 GTAAAA CGACGGCCAGT Sense primer to verify pTEX-TRYS integrity (plasmid backbone) 
P26 ACAGGAAACAGCTAT GA Anti-sense primer to verify pTEX-TRYS integrity (plasmid backbone) 
P27 ccggaattcATGGGATCGGCCATTGAA Sense primer to amplify NEO ORF 
P28 cgcggatccTCAGAAGAACTCGTCAAG Anti-sense primer to amplify NEO ORF 
 
3. Transformation of Escherichia coli  
Escherichia coli DH5α competent cells, used in the generation of plasmid constructs, 
were obtained following the calcium chloride (CaCl2) method [100]. Transformations were 
performed by incubating E. coli with 50-80 ng of DNA on ice for 30 min, followed by a heat 
shock at 42 ºC and incubation in SOC medium for 1 h at 37 ºC with shaking. Transformed cells 
were plated in LB-agar medium with 50 µg ml
-1
 ampicillin and incubated O/N at 37 ºC.  
4. General cloning procedures 
DNA fragments were PCR-amplified with the high fidelity PWO polymerase (Roche
®
) 
from the L. infantum genome and subsequently cloned into the appropriate vectors for 
propagation in E. coli. Assembling reactions were performed using T4 DNA ligase 
(Fermentas
®) according to the manufacturer’s instructions. Positive colonies were tested by 
PCR and the accuracy of the assembled constructs verified by DNA standard sequencing in 
Macrogen (Europe). Constructs were purified from E. coli using GenElute
TM
 Plasmid Miniprep 
kit (Sigma
®
).   
5. Generation of TRYS transfection constructs 
Two DNA constructs carrying different drug resistance markers were generated to 
replace both TRYS alleles by homologous recombination. To that end, part of the 5’ and 3’ non-
coding sequences flanking the TRYS ORF (5’NCS and 3’NCS, for short) were PCR-amplified 
from the L. infantum genome using the pairs of primers P1/P2 and P3/P4, respectively. 
Following digestion with the appropriate restriction enzymes, the 3’NCS was cloned into the 
BamHI-SacI sites of the pGL345-TXN1KØ and of the pGL726-TXN1KØ plasmids, previously 
used to target the LiTXN1 ORF [67], which carry the hygromycin phosphotransferase (HYG) 
gene and the phleomycin hydrolase (PHLEO) gene, respectively. The resulting constructs were 
subsequently digested with HindIII-SpeI restriction enzymes to accommodate the 5’NCS of L. 
infantum TRYS. Before transfection of L. infantum promastigotes, constructs were linearized 
with HindIII and SacI and purified from agarose gels using the QIAquick
®
 II Gel Extration Kit 
250 (Qiagen).  
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The TRYS episome was generated by cloning the TRYS ORF into the trypanosomatid 
expression vector pTEX-NEO [98]. To that end, the TRYS ORF, previously cloned in our lab in 
frame with a 6-histidine tag in the NdeI/XhoI restriction sites of pET28c (Novagen
®
), was 
excised using the BglII/XhoI enzymes and cloned into the BamHI/XhoI sites of pTEX-NEO. The 
resulting plasmid was subsequently digested with NdeI and EcoRI restriction enzymes followed 
by Klenow treatment and religation, in order to remove the 6-histidine coding sequence 
upstream the TRYS ORF.  
6. Generation of GSPS transfection constructs 
Two DNA constructs carrying different drug resistance markers were generated to 
replace both GSPS alleles by homologous recombination. Accordingly, part of the 5’NCS and 
3’NCS flanking the GSPS ORF were PCR-amplified from the L. infantum genome using the 
pairs of primers P15/P16 and P17/P18, respectively. The 5’NCS was cloned into the HindIII-
SpeI sites of the pGL434 vector, which carries the blasticidin S deaminase (BSD) gene, 
followed by insertion of the 3’NCS into the BamHI-BglII sites. The second replacement 
construct was obtained by replacing the BSD gene in the previously assembled plasmid, by the 
puromycin N-acetyl-tranferase (PAC) gene, excised from pGL701 by SpeI-BamHI restriction. 
Before transfection of L. infantum promastigotes, constructs were linearized with the restriction 
enzymes HindIII-BglII and purified from agarose gels using the QIAquick
®
 II Gel Extration Kit 
250 (Qiagen).    
  
7. Leishmania infantum transfections 
Transfections were performed in an Amaxa
®
 Nucleofector
TM
 (Lonza
®
), using the 
program U-033. Briefly, 5x10
7
 log-phase promastigotes, suspended in Human T cells 
nucleofactor buffer (Lonza
®
), were transfected with 2 to 10 μg of DNA and immediately 
transferred into flaks containing 10 ml of RPMI complete medium. These were then split into 
two 5 ml cultures and allowed to recover. Twenty four hours latter, selective drugs were added 
to 5 ml of the liquid cultures and the remaining 5 ml were pelleted and plated onto agar plates 
containing the same drug(s). Geneticin (G418; Sigma
®
) was used at 15 μg ml-1, hygromycin 
(Invitrogen
®
) at 10 µg ml
-1
, phleomycin (Sigma
®
) at 17.5 µg ml
-1
, blasticidin S (Sigma
®
) at 30 
µg ml
-1
 and puromycin (Sigma
®
) at 20 µg ml
-1
. Upon 2 to 3 weeks of growth on agar, colonies 
were transferred into liquid medium and tested for the correct acquisition of the transfected 
DNA.  
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8. Cryopreservation of L. infantum 
Promastigotes in logarithmic-phase of growth were suspended at 2x10
8
 cells ml
-1
 in 
RPMI medium supplemented with 20% FBSi, 50 U ml
-1
 penicillin, 50 µg ml
-1
 streptomycin and 
15 % (v/v) dimethyl sulfoxide (DMSO). Cryotubes were placed in an isopropanol container 
previously cooled at 4ºC and incubated for 2 to 18 hours at -70 ºC before being stored in liquid 
nitrogen. 
9. Preparation of genomic DNA from L.infantum 
Two different protocols were used to extract genomic DNA from L. infantum parasites. 
For analysis of isolated clones Puregen Core Kit A (Qiagen) was used according to the 
manufacturer's instructions. For Southern blot, genomic DNA was isolated following a 
phenol/chloroform extraction protocol [101]. 
10. Southern blot 
Southern blots were preformed according to standard protocols [102]. Total genomic 
DNA was digested with the SacII restriction enzyme, resolved in 0.7% agarose gel and 
transferred onto Hybound-N+ nylon membrane (Amersham Bioscience
®
). Probes were labeled 
with [α-32P] dCTP using RedPrime II Random Prime Labeling System (AmershamTM GE 
Healthcare) according to the manufacturer’s instructions.    
11. Western blot 
L. infantum protein extracts were obtained by solubilizing 10
9
 cells ml
-1
 in 1% (v/v) 
Nonidet P-40 (Sigma
®
) in PBS in the presence of a cocktail of protease inhibitors. Protein 
concentration in the extracts was determined by absorbance reading at 280 nm in Nanodrop 
spectrophotometer ND-1000. Extracts containing 1% β-mercaptoethanol were fractionated in a 
10 % SDS-polyacrylamide gel electrophoresis and electroblotted onto Hybound-C+ nitro 
cellulose membranes (Amersham Bioscience
®
). The membranes were subsequently probed with 
anti-LmTRYS primary antibody, kindly provided by Alan Fairlamb (University of Dundee, 
UK). Secondary antibody was ECL
TM
 horseradish-conjugated anti-rat IgG (Amersham
TM
 GE 
Healthcare). To control for sample loading, membranes were stained by incubation with 
Ponceau reagent for 15 minutes or with Sypro
®
 Ruby Protein Blot Stain S-11791 (Molecular 
probes
®
) accordingly to manufacturer's instructions. Detection was performed using Super 
Signal
®
 West Dura Extended Duration Substrate or Super Signal
®
 West Pico Chemiluminescent 
Substrate detection reagents (Thermo Scientific). 
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12. Growth curves 
For growth rate determination L. infantum promastigotes, previously synchronized, 
were seeded at 10
6
 cells ml
−1
 and cell density monitored daily for 6 days with a hemocytometer. 
13. N
5
-substituded paullones 
For the chemical validation of TRYS four compounds were selected from a collection of 
N
5
-substituted paullones chemically synthetized and tested in vitro against purified recombinant 
LiTRYS by Molisa GmbH (Germany). All compounds were solubilized in 100% DMSO to a 
final concentration of 50 mM. 
14. Isolation of murine peritoneal macrophages 
Macrophages were obtained by peritoneal lavage of National Marine Research Institute 
(NMRI) mice from the animal house facility of the Institute for Molecular and Cell Biology 
(IBMC). To allow the formation of macrophages monolayers, 3x10
5 
cells per well were seeded 
in 24-well plates with round glass coverslips and allowed to adhere overnight in DMEM 
Glutamax
TM 
culture medium supplemented with 20% FBSi, 50 U ml
-1
 penicillin and 50 µg ml
-1
 
streptomycin (complete DMEM medium) at 37ºC in 5% CO2 atmosphere. For some 
experiences, murine macrophages were seeded at 8x10
4
 cells per well in 96-well plates.   
15. Leishmanicidal effect of N
5
-substituded paullones on intracellular amastigotes  
Monolayers of peritoneal murine macrophages were incubated with stationary-phase 
promastigotes (7-8 days culture) at a ratio of 10 parasites to 1 macrophage, for 3 hours at 37 ºC 
and 5% CO2, in 24-well plates. Non-internalized parasites were removed by washing with pre-
warmed DMEM medium and infected macrophages were cultured for 24 h in complete DMEM 
medium. To determine the effect of drugs in parasite survival, varying concentrations of FS-
304, FS-554, FS-528 and FS-99a, were added to infected macrophages, keeping the DMSO 
concentration at 0,5% (v/v). Control cells were incubated without drugs with 0,5% (v/v) DMSO. 
Cells were grown for additional 48 h prior to being labeled for immunofluorescence analysis. 
To that end, monolayers of infected macrophages in round coverslips were fixed with methanol 
for 15 min at -20 ºC, permeabilized with 0.1% (v/v) Triton X-100 in PBS and blocked with 1% 
bovine serum albumin (BSA). Cells were incubated with a cocktail of primary anti-bodies (anti-
LicTXNPx1 + anti-LimTXNPx [62]) for 1 h, washed with PBS, incubated for 1 h with the 
Alexa Fluor 488 anti-rabbit IgG (Molecular Probes) secondary antibody and for 15 min with a 
mixture of propidium iodide and 4',6-diamidino-2-phenylindole (DAPI). Samples were mounted 
in 70% (v/v) glycerol in PBS, examined with AxioImager Z1 fluorescence microscope and 
photographed with an Axiocam MR 3.0 using the Axiovision 4.6 software (Carl Zeiss). A 
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minimum of 4000 macrophages were counted per experimental condition using the CellNote 
software [103]. 
16. Detection of nitric oxide production in macrophages 
Nitric oxide production was estimated indirectly by determination of nitrite (NO2
-
) 
concentration in macrophage cultures following the Griess assay [104]. Concentration of NO2
-
 
was determined in cultures supernatants by 1:1 addition of Griess reagent (1% sulfanilamide, 
0.1% naphthalene-ethylenediamine dihydrochloride, 2.5% H3PO4) and measuring product 
formation (an Azo compound) spetrophotometrically at 550 nm. Increasing quantities of NaNO2 
were used as standards following the same treatment of samples.     
17. Cell viability assays 
Determination of cell susceptibility towards FS-554 was addressed using resazurin 
sodium salt (Sigma
®
). Fluorescence of the resorufin product was measured (excitation 560 nm; 
emission 590 nm) using a Spectra Max Gemini XS Microplate Spectrofluorometer (Molecular 
Devices
®
). Cell viability was determined considering the signal of cultures with 0 µM FS-554, 
0,5 % (v/v) DMSO as 100% viability.  
17.1. Promastigote viability 
Synchronized promastigote cultures were seeded at 10
6
 cells ml
-1
 in 24 well-plates in 
complete RPMI medium with varying concentrations of FS-554 and incubated for 48 h at 25 º 
C. Resazurin solution was added to a final concentration of 250 µM and fluorescence measured 
after 24 h, 48 h and 96 h. Data was analyzed with Graphpad prism 5 software and EC50 values 
determined with non-linear fit using a two-parameter equation:  
 
17.2. Macrophages viability 
Murine macrophages monolayers were seeded at 8x10
4
 cells per well in 96-well plates 
and allowed to adhere O/N in complete DMEM medium at 37 ºC and 5% CO2. Varying 
concentrations of FS-554 were added and cells incubated for 48 h at 37 ºC and 5% CO2. 
Resazurin solution was added to a final concentration of 125 µM and flourescense measured 
after 24h. 
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18. Geneticin-resistance assays 
 Promastigote cultures were seeded at 10
6
 cells ml
-1
 in RPMI complete medium with 50 
µg ml
-1
 G418 and without drug. Cells were counted 4-7 days after the addition of G418 and the 
data expressed as a percentage of parasite replication in control cultures without drug addition. 
19. In vivo mice infections 
 BALB/c mice were infected by intra-peritoneal injection with 10
8
 stationary-phase 
promastigotes in PBS. Animals were sacrificed at determined time points after infection and 
their livers and spleens homogenized in complete RPMI medium, incubated at 25 ºC and 
differentiated promastigotes cultured for further analysis. 
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